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CHAPTER 1. INTRODUCTION 
The 2006 Institute of Medicine (IOM) report “From Cancer Patient to 
Cancer Survivor: Lost in Transition” recommends “health care providers should 
use systematically developed evidence-based clinical practice guidelines, 
assessment tools, and screening instruments to help identify and manage late 
effects of cancer and its treatment.” Without these guidelines, the practices of 
health care providers will vary widely, leading to inefficiencies in the delivery of 
care. The report emphasizes the need for evaluating the impact of guidelines in 
the context of cancer care.  
Spending on medical treatment for cancer in the United States accounts 
for nearly 103 billion dollars annually, with the administering of chemotherapy 
agents driving the cost of treating advanced stages of the disease. 
Understanding the extent to which chemotherapy use in practice is consistent 
with these guidelines as well as the factors associated with inappropriate 
chemotherapy use has rarely been studied among large populations, mainly 
because performance status (PS), a key clinical component in assessing 
chemotherapy appropriateness, is typically missing from claims-based 
databases. The purpose of PS is to quantify the general well-being of a cancer 
patient. It is used to determine whether patients can receive chemotherapy, 
whether dose adjustment is necessary, as a measure for the required intensity of 
palliative care, and as a quality of life measure in randomized controlled trials. 
The goal of this research is to quantify the non-guideline concordant use 
of chemotherapy within an insured population diagnosed with lung cancer with 
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documented PS, and to evaluate the factors associated with under- and over-use 
of chemotherapy within this cohort.  By combining data from medical records with 
those available via an automated tumor registry, medical claims, and Census 
data, I was able to consider the patients’ clinical and socio-demographic 
characteristics, as well as characteristics of the neighborhoods in which the 
patients reside. 
A key factor in evaluating appropriateness of chemotherapy in lung cancer 
is the “performance status” (PS) of the patient.  PS is a subjective measure used 
by clinicians to assess functional capacity and the likelihood of adverse events, 
quality of life, and survival after treatment. Measures of PS are currently not 
available through automated claims data. This void acts as an impediment in 
comparative effectiveness research. In chapter 2, I develop a tool to estimate PS 
using claims-based measures. I used chart abstracted PS (from the medical 
record) and linked it to automated medical and pharmaceutical claims and tumor 
registry data.  
In chapter 3, I describe the sample of chemotherapy users and nonusers 
and examine the factors associated with underuse and overuse of 
chemotherapy. Patients with good PS, for whom chemotherapy treatment is 
recommended, who did not receive chemotherapy are classified as under-users. 
Patients with poor PS, who received chemotherapy despite guideline 
recommendations against its use, are classified as over-users. I use logistic 
regression to estimate two models. The first model tests non-receipt of 
chemotherapy among patients with good PS and the second considers the 
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receipt of chemotherapy among patients with poor PS. In both models, I consider 
patient-level characteristics including demographic, clinical, socioeconomic, and 
health care access measures.  
In the final chapter, I focus on the outcomes associated with the choice of 
adherence to guidelines. Specifically, I am evaluating the relationship of over- 
and under-use with survival. To account for the endogeneity of chemotherapy 
receipt in estimating outcomes I use a two-stage residual inclusion (2SRI) model. 
The first stage equation represents a logistic regression for factors associated 
with receipt of chemotherapy (same equation from chapter 3). For survival, the 
second stage equation is the Cox proportional hazard model. 
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CHAPTER 2. USING CLAIMS-BASED MEASURES TO PREDICT 
PERFORMANCE STATUS IN PATIENTS WITH LUNG CANCER 
 
Performance status (PS) is a good prognostic factor in lung cancer and is 
used to assess chemotherapy appropriateness. Researchers studying 
chemotherapy use are often hindered by the unavailability of PS in automated 
data sources. To my knowledge, no attempts have been made to estimate PS 
using claims-based measures. The current study explored the ability to estimate 
PS using routinely available measures.  
A cohort of insured patients aged ≥ 50 years who were diagnosed with 
American Joint Committee on Cancer stage II through IV lung cancer between 
2000 and 2007 was identified via a tumor registry (n = 552). PS was abstracted 
from medical records. Automated medical and pharmaceutical claims from the 
year preceding diagnosis were linked to tumor registry data. A logistic regression 
model was fit to estimate good versus poor PS in a random half of the sample. C 
statistics, sensitivity, specificity, and R2 were used to compare the predictive 
ability of models that included demographic factors, comorbidity measures, and 
claims-based utilization variables. Model fit was evaluated in the other half of the 
sample. 
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2.1 Introduction 
Since 1997, evidence-based guidelines have recommended the use of 
chemotherapy for medically fit patients with lung cancer to improve survival, 
symptoms, and quality of life (1997;2010c;D. G. Pfister et al. 2004;2010b). 
Despite these recommendations, numerous studies (T. J. Smith et al. 1995;P. B. 
Bach et al. 1999;C. C. Earle et al. 2000;A. L. Potosky et al. 2004) have illustrated 
variability in the receipt of chemotherapy among patients with lung cancer. 
Nevertheless, the ability to determine the appropriateness of observed treatment 
variability has been greatly hindered by voids in the clinical information 
necessary to judge appropriateness. 
One key factor in evaluating the appropriateness of chemotherapy is the 
patient’s performance status (PS) (1997;2010b;2010c;D. G. Pfister et al. 2004). 
PS is a subjective composite measure used by clinicians to assess current 
functional capacity and the likelihood of adverse events, quality of life, and 
survival after treatment. Measures of PS are currently not available through 
automated medical claims, tumor registries, or other observational data 
commonly used to study cancer treatment and its associated outcomes. Thus, 
the use of such data to address questions regarding chemotherapy has been 
relatively limited and when undertaken, the inability to consider PS is a noted 
limitation (A. L. Potosky et al. 2004;B. E. Hillner et al. 1998;C. J. Bradley et al. 
2008). The systematic lack of information regarding PS similarly impedes the 
ability of researchers to use existing automated, observational data for 
comparative effectiveness research. 
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This chapter asks two questions. First, how often are measures of a 
patient’s PS documented in his or her detailed medical record? Second, is it 
possible to accurately estimate a patient’s PS using routinely available tumor 
registry and claims- based measures on that patient’s demographics, 
comorbidities, and prior healthcare utilization? By using a cohort of lung cancer 
patients diagnosed between 2000 and 2007, the feasibility of using medical 
record documentation to obtain PS measures was described overall and by 
patient characteristics. Medical record-documented PS information was then 
combined with information routinely available in an automated tumor registry as 
well as medical and pharmaceutical claims data to evaluate the feasibility of 
estimating PS among lung cancer patients using information routinely available in 
observational data sources. To my knowledge, this has not previously been 
attempted among patients with lung or other cancers. 
 
2.2 Materials and Methods 
Study Population and Setting 
Study patients were those receiving care from a 900-physician member, 
multispecialty, salaried medical group practice in southeast Michigan. Data 
available from the medical group’s tumor registry were used to identify all 
patients aged ≥ 50 years who were diagnosed with lung cancer between January 
1, 2000 and December 31, 2007. The medical group, which provides care under 
both fee-for-service and capitated arrangements, staffs 27 primary care clinics 
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throughout Detroit and the surrounding metropolitan area. Patients eligible for 
study inclusion were those continuously enrolled in an affiliated health plan 
(i.e., health maintenance organization) for the 1-year period preceding their date 
of lung cancer diagnosis. Patients for whom no stage of disease was available at 
the time of diagnosis or for whom the stage at diagnosis was 0 to I were 
excluded because chemotherapy was not indicated for patients with stage 0 or I 
disease during this time period (W. J. Scott et al. 2007). The medical group’s 
Institutional Review Board approved all aspects of the study protocol. 
 
PS Measurement 
The 2 most commonly used PS systems are the Eastern Cooperative 
Oncology Group (ECOG) scale and the Karnofsky performance scale (KPS) (S. 
P. Blagden et al. 2003). Although the 2 scales are not identical, they are 
generally believed to capture the 
same conceptual domain and conversions are possible between them (Table 1) 
(G. Buccheri et al. 1996). Two trained chart abstractors reviewed inpatient and 
outpatient nursing and physician notes available within the patient’s electronic 
medical record from 2 months before diagnosis until the first notation of death, 
disenrollment, initiation of chemotherapy, or 6 months after diagnosis. If 
available, abstractors documented specific numeric PS and scale (i.e., ECOG or 
KPS). Patients were assigned a good PS if they had an ECOG score of 0 or 1 or 
a KPS score of 80 to 100. A poor PS was assigned to patients with an ECOG 
score of 2 to 5 or a 
8 
 
 
 
KPS score of 0 to 70. This was done to be consistent with standards in practice 
regarding recommendations for chemotherapy use among lung cancer patients 
during the study period (1997;2010b;2010c;D. G. Pfister et al. 2004), as well as 
with existing research applications (R. C. Lilenbaum et al. 2008), With the 
issuance of the 2009 American Society of Clinical Oncology (ASCO) guidelines, 
the standard for chemotherapy use changed to include the consideration of use 
in those patients with an ECOG score of 2 or a KPS score of 60 to 70. Thus, we 
also presented alternative results for which those patients with these scores were 
realigned to a good PS. 
If no numeric score was documented, abstractors collected medical record 
documentation of good or poor PS. If no reference to PS was documented in the 
medical record, notes regarding the patient’s functionality (e.g., references to 
shortness of breath, use of a wheelchair or other personal mobility devices, labor 
force participation, exercising habits, activities of daily living, or other references 
to mobility) were recorded and used to estimate PS. Inter-rater reliability between 
the 2 abstractors was assessed on a random subset of 40 observations. The 
resulting Cohen κ was 0.88. Among the inter-rater reliability subset (N = 40), in 
each incident in which the abstracted PS did not match between the 2 
abstractors (3 cases), 1 abstractor indicated good or poor whereas the other 
selected unknown PS. For the final analytical database, these differences were 
reconciled by choosing good/poor over unknown. 
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Automated Tumor Registry and Claims Data 
Automated tumor registry and claims data were used to obtain patient 
demographic characteristics, cancer stage, and diagnoses for each patient. 
Demographic measures included age, gender, and race. The age of the patient 
(in years) was recorded as of the date of lung cancer diagnosis. Clinical variables 
examined included stage of disease at the time of diagnosis and the Charlson 
comorbidity index (M. E. Charlson et al. 1987). Cancer stage was reported using 
the American Joint Committee on Cancer (AJCC) stages II through IV. A 
dichotomous variable was created to control for AJCC stage IV patients in the 
regression analysis. The Deyo adaptation of the Charlson comorbidity index and 
each of its component diagnostic subgroups were constructed using inpatient 
and outpatient diagnostic information available in the 12-month period preceding 
diagnosis (R. A. Deyo et al. 1992). In addition, claims data provided information 
regarding prescription drugs dispensed and medical care use within the 12-
month period preceding lung cancer diagnosis. 
Medical care use measures included those reflective of inpatient stays in a 
short-stay hospital or skilled nursing facility (SNF); ambulatory care visits; 
emergency department visits; and use of home health services, same-day 
surgery, and durable medical equipment (DME). For each person, inpatient use 
measures included the total number of distinct inpatient stays, the total number of 
inpatient days, and the average length of an inpatient stay for those with a non-0 
number of stays. The number of outpatient visits was recorded, and in the 
regression analysis a dichotomous variable was created to control for patients 
10 
 
 
 
with non-0 outpatient visits. Similar dichotomous variables were constructed to 
reflect any drug dispensing and any DME use. The emergency department, 
home health, and same-day surgery use variables measured the counts of visits 
incurred. We also evaluated the use of a count of the distinct number of 
medications dispensed during the baseline year, as recommended by 
Schneeweiss et al (S. Schneeweiss et al. 2001). For this measure, medications 
whose first 8 digits of the American Hospital Formulary Services code were equal 
were considered to be the same drug (2010a). 
 
Statistical Analysis 
Among the cohort of lung cancer patients, we reported the frequency of 
documented PS in medical records and described the different ways PS was 
recorded. Systematic differences between patients for whom PS was recorded 
and patients for whom it was not recorded were examined using 2-sample 
Student t tests (or Wilcoxon rank sum tests) and chi-square tests, depending on 
the nature of the characteristic. Similar analyses were conducted to compare 
unadjusted differences in patient characteristics by good PS versus poor PS. 
Multivariable logistical regression models were fit to evaluate the feasibility of 
using routinely available observational data to predict good versus poor PS. 
Three separate models were estimated, reflective of 3 different levels of the 
comprehensiveness of observational data routinely available. The first regression 
model included only those variables typically available via tumor registries 
(demographics and stage of disease). The second model included those same 
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variables plus measures of medical care use and diagnoses available in medical 
claims data. The third model added measures of prescription drug use routinely 
available via pharmaceutical claims. 
For each model, a split-sample cross validation was used to check for 
model overfitting. C statistics, sensitivity, specificity, and R2 were used to assess 
and compare the predictive ability of the different models. Initially, all variables 
were considered for inclusion. However, the final model in each of the 3 
categories was fit using the stepwise elimination method. Pairwise interactions 
were tested but were not found to enhance model prediction. Likewise, we 
evaluated the need to account for the non-independence of patients seen by the 
same physician, but because the intra-class correlation coefficient (ICC) was 
negligible (ICC = 0.01), we elected not to do so because not doing so enabled us 
access to additional assessment of model fit. The final models were estimated on 
the full sample and bootstrapping was used to replicate each final model 1000 
times to create 95% confidence intervals around the c and R2 statistics (B. Efron, 
G. Gong 83 A.D.). 
To examine model discrimination, patients were ranked by their predicted 
probability of good PS based on each model. Patients were then divided into 
deciles based on increasing predicted probability of good PS and actual good PS 
rates were reported among patients in all deciles to suggest how well models 
separated patients with good PS from those with poor PS (S. Lemeshow, D. W. 
Hosmer, Jr. 1982). SAS statistical software (version 9.1.3; SAS Institute Inc, 
12 
 
 
 
Cary, NC) was used for all analyses. P < .05 was considered to be statistically 
significant. 
 
13 
 
 
 
Table 1. The Eastern Cooperative Oncology Group (ECOG) Performance Status 
Score (PS) and its Karnofsky PS Equivalent 
 
ECOG Karnofsky 
Grade Description 
0 Fully active, able to carry on all pre-disease performance 
without restriction 
100 
1 Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature (e.g., light 
house work, office work) 
80-90 
2 Ambulatory and capable of all self care but unable to carry 
out any work activities. Up and about more than 50% of 
waking hours 
60-70 
3 Capable of only limited self care, confined to bed or chair 
more than 50% of waking hours 
40-50 
4 Completely disabled. Cannot carry on any self care; confined 
to bed or chair 
20-30 
5 Dead 0-10 
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2.3 Results 
Cohort Characteristics 
A total of 552 patients met the criteria for study eligibility. The mean age of 
the patients at diagnosis was 67.4 years (standard deviation [SD], 9.1 years). Of 
the patients eligible for the study, 42% were female, whereas the racial 
distribution was 69% white and 31% black. The AJCC staging distribution was as 
follows: 9% of patients were diagnosed with stage II disease, 20% with stage IIIA 
disease, 19% with stage IIIB disease, and 52% with stage IV disease. The 
average Charlson comorbidity index across the eligible sample was 2.8 (SD, 
3.4), whereas the average number of distinct prescription drugs used in the year 
before diagnosis was 9.3 (SD, 7.1).  
The average number of inpatient days in the year before diagnosis for the 
cohort (including those with no inpatient stays) was 2.9 days (SD, 7.5 days), 
whereas the average number of inpatient stays was 0.5 (SD, 0.8), resulting in an 
average inpatient length of stay of 5.0 days (SD, 5.2 days). The average number 
of outpatient visits was 5.7 (SD, 8.5) and the average number of emergency 
department visits was 0.6 (SD, 1.1) for the same time period. Across the study-
eligible sample, 28% recorded any home health use, 3% had same-day surgery, 
12% incurred a DME dispensing, and 4% incurred a stay in a rehabilitation facility 
or SNF. None incurred a hospice stay in the period before the lung cancer 
diagnosis. 
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Medical Record Documentation of PS 
Of the 552 study eligible patients, PS was recorded in the medical record 
for 261 cases (47%). Among these, a numeric score was documented in 248 
cases (95%), with the ECOG scale most often used (74%). For the remaining 
13 patients, although a numeric score was not documented, explicit 
documentation was found of either good or poor PS. 
Among the 291 (53%) patients for whom PS was not recorded, there were 
181 for whom there was a sufficient verbal description of the patient’s functioning 
in either the physician’s notes, nurse’s notes, or a combination of both to enable 
a determination of either a good or poor PS score. Thus, overall there were 442 
patients (80%) for whom PS was determinable in their medical record. 
Differences in patient characteristics by PS documentation level are 
reported in Table 2. The first 2 columns compare those patients for whom 
medical record documentation could be used to determine PS (known PS) with 
those for whom medical record documentation was insufficient to determine PS 
(unknown PS). As shown, patients with unknown PS (n = 110) did not differ 
significantly from those with a known PS (n = 442) with regard to demographic or 
clinical characteristics or measures of medical care use. 
Among patients with a known PS, the third and fourth columns of Table 2 
compare patient characteristics between those who had a documented PS 
(either numeric or verbal) with those for whom a PS was extrapolated based on 
notes in the medical record. No significant differences were observed for most 
measures. However, there were significant differences by gender, diagnosis of 
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atherosclerotic cardiovascular disease, and the average number of inpatient 
days. 
 
Patient Factors Associated With PS 
Among the 442 patients for whom PS was known, 290 patients (66%) had 
a good PS using the pre-2009 definition of good and 152 (34%) had a poor PS. 
This changed to 76% with a good PS and 24% with a poor PS when those with a 
documented numeric PS of 2 were considered to have good PS, as would be 
consistent with that in the 2009 ASCO guidelines for the use of chemotherapy. 
The unadjusted differences in patient characteristics by PS are illustrated in 
Table 3. Compared with patients with good PS, patients with poor PS were 
significantly older (69.7 years vs. 66.4 years) and more likely to be male (66% vs. 
54%), have stage IV disease (64% vs. 44%), and have a significantly higher 
Charlson comorbidity index (3.6 vs. 2.4). Consistent with the latter finding, 
patients with poor PS were significantly more likely to have been diagnosed with 
several of the individual components of the Charlson comorbidity index when 
compared with those with good PS. Patients with poor PS also incurred 
significantly more inpatient days (5.5 days vs. 1.7 days) as well as longer lengths 
of stay (6.8 days vs. 5.4 days) in the year before diagnosis, and were more likely 
to have incurred any outpatient visit, home health use, or DME use in the year 
before diagnosis. Also of note is that patients with poor PS were significantly less 
likely to have undergone chemotherapy in the year after diagnosis (42% vs. 82%) 
(data not shown). Similar differences between the groups were found when those 
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with a PS of 2 were realigned with the good PS group, with 2 exceptions: 
statistically significant differences in gender and the prevalence of peripheral 
vascular disease no longer existed. 
 
Predicting Performance Status 
Results from the logistical regression models predicting good versus poor 
PS defined the 2 ways are presented in Table 4. Results are presented for 
models fit on the full sample and include only significant (P < .05) variables per 
the stepwise regression. In the model that included only tumor registry variables, 
only age at diagnosis and AJCC stage were selected (Model 1). Diagnosis of 
chronic pulmonary disease, the number of inpatient stays, any outpatient visits, 
and the number of emergency department admissions were all added when 
information from medical claims data were considered (Model 2). One more 
variable, the number of distinct prescription drugs, was added when information 
from pharmaceutical claims data was considered (Model 3). 
Statistical performance improved with the inclusion of additional 
explanatory variables (Table 4). Cross-validated C and R2 values were never 
more than 0.01 smaller than fitted values. By using a predictive threshold of 0.50, 
a high sensitivity (0.88 or 0.94, depending on how good PS was defined) was 
obtained with the best model (Model 3), but with moderate specificity (0.45 or 
0.32). Increasing the predictive threshold to 0.70 continued to yield relatively high 
sensitivity (0.64 or 0.83) and more moderate specificity (0.69 or 0.55), regardless 
of how good PS is defined. 
18 
 
 
 
Table 5 shows the actual and predicted good PS rates for patients within 
each of the 10 deciles. As measured by the Hosmer-Lemeshow chi-square 
statistic (S. Lemeshow, D. W. Hosmer, Jr. 1982), all models had good calibration, 
in which actual and predicted rates within each of the 10 deciles were not 
significantly different (P = .69, P = .32, and P = .13 for Models 1-3, respectively) 
when a PS of 2 was defined as poor and likewise not significantly different (P = 
.92, P = .63, and P = .98 for Models 1-3, respectively) when a PS of 2 was 
defined as good. Model discrimination was also improved with the inclusion of 
more explanatory variables. 
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Table 2. Sample Characteristics, and Prescription Drug and Medical Care 
Utilization in the Year Prior to Diagnosis of Lung Cancer, by Performance Status 
(PS) documentation level, (n = 552) 
 
Characteristic Unknown 
PS 
(n =110) 
Known PS 
(n = 442) 
Documented 
PS 
(n = 261) 
Extrapolated 
PS  
(n = 181) 
Demographic Characteristics     
Average diagnosis age (SD) 66.9 (9.9) 67.5 (8.8) 68.0 (8.6) 66.9 (9.2) 
Gender (%)     
          Female  45 42 38* 48* 
          Male  55 58 62 52 
Race (%)     
          Asian   0   1   1   0 
          Black 31 30 28 34 
          White 69 69 71 66 
Clinical Characteristics     
AJCC stage (%)     
          II   4 11 10 11 
          IIIA 17 20 19 22 
          IIIB 24 18 17 20 
          IV 54 51 54 47 
Average Charlson score (SD)   2.7 (3.6)   2.8 (3.3)   2.9 (3.5)   2.7 (3.1) 
   Atherosclerotic cardiovascular disease (%) 15.4 21.3 24.5* 16.6* 
   Congestive heart failure (%)  16.4 17.4 18.4 16.0 
   Ischemic heart disease (%)    8.2   9.3 10.3   7.7 
   Peripheral vascular disease (%)  11.8 13.4 14.2 12.2 
   Dementia (%)   0.9   1.1   1.5   0.6 
   Pelvic ulcer disease (%)    2.7   3.6   3.8   3.3 
   Rheumatologic disease (%)   5.4   6.3   6.1   6.6 
   Chronic pulmonary disease (%)  32.7 41.4 41.4 41.4 
   Liver disease (%)   2.7   1.4   0.8   2.2 
   Diabetes (%) 19.1 28.3 29.9 26.0 
   Diabetes with complications (%)   4.6   4.5   4.2   5.0 
   Paralysis (%)   1.8   0.9   1.1   0.6 
   AIDS (%)   1.8   1.1   1.1   1.1 
   Cancer (%) 24.6 29.9 28.0 32.6 
   Cancer with metastasis (%)   5.4   7.5   8.0   6.6 
   Renal disease (%)    6.4   5.7   6.1   5.0 
   Aneurysm (%)   6.4   6.3   7.3   5.0 
   Gangrene (%)   0.9   0.7   0.8   0.6 
Prescription Drug Utilization   
  
Average no. of dispensings (SD)   8.7 (7.0)   9.4 (7.1)   9.5 (7.1)   9.3 (7.2) 
 Pct with ≥ 1 dispensing 85 89 91 86 
Medical Care Utilization     
Average no. IP days (SD)    2.7 (6.8)   3.0 (7.7)   2.4 (5.1)*   3.9(10.4)* 
Average no. IP stays (SD)   0.4 (0.7)   0.5 (0.8)   0.4 (0.7)*   0.6 (0.8)* 
Average length of IP stays (SD)   5.8 (5.2)   6.1 (5.2)   6.0 (5.3)   6.1 (5.0) 
Average no. of OP visits (SD)   5.9 (8.3)   5.6 (8.6)   5.7 (9.1)    5.5 (7.8) 
Pct with ≥ 1 OP visit 75 76 77 76 
Average ≥ 1 ED visit  (SD)   0.7 (1.0)   0.6 (1.1)   0.7 (1.2)   0.5 (1.0) 
Pct with ≥ 1 home health claim 25.4 29.0 31.4 25.4 
Pct with ≥ 1 ambulatory surgery claim   2.7   3.2   3.4   2.8 
Pct with ≥ 1 rehabilitation/SNF claim    4.6   3.8   5.0   2.2 
Pct with ≥ 1 DME claim3   10.9 12.0 13.4   9.9 
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1 Among all patients (including those with no inpatient stays). 
2 No. of inpatient days divided by no. of inpatient stays – among patients with at least one 
inpatient stay. 
3 DME included claims for portable oxygen, walkers, canes, wheelchairs, and hospital beds. 
* Significant difference at 5% level. 
Abbreviations: standard deviation (SD); percent (Pct); number (no.); American Joint Committee 
on Cancer (AJCC); inpatient (IP); outpatient (OP); emergency department (ED); skilled nursing 
facility (SNF); durable medical equipment (DME).  
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Table 3. Among Patients with Known Performance Status (PS), Sample 
Characteristics, and Prescription Drug and Medical Care Utilization in the Year 
Prior to Diagnosis of Lung Cancer, by PS (n=442) 
 
Characteristic 
 
 
Pre 20091 Post 20092 
Good PS 
( n = 290 ) 
Poor PS 
( n = 152 ) 
Good PS 
( n = 336) 
Poor PS 
( n = 106 ) 
Demographic Characteristics  
   
Average diagnosis age (SD) 66.4 (9.1)* 69.7 (7.9)* 66.8 (8.9)* 70.0 (8.1)* 
Gender (%)      
          Female  46* 34* 43 38 
          Male  54 66 57 62 
Race (%)     
          Asian   1   1   1   0 
          Black 28 34 28 38 
          White 71 65 71 62 
Clinical Characteristics  
   
AJCC Stage (%)     
          II 13   7 11   9 
          IIIA 24 13 23 11 
          IIIB 19 16 19 17 
          IV  44* 64* 47* 63* 
Average Charlson score (SD)   2.4 (3.0)*   3.6 (3.8)*   2.5 (3.1) *   3.9 (3.9) * 
   Atherosclerotic cardiovascular disease (%) 19.3 25.0 19.9 25.5 
   Congestive heart failure (%) 12.1* 27.6* 14.3* 27.4* 
   Ischemic heart disease (%)   6.6* 14.5*   7.7* 14.2* 
   Peripheral vascular disease (%) 10.3* 19.1* 12.2 17.0 
   Dementia (%)   0.0*   3.3*   0.0*   4.7* 
   Pelvic ulcer disease (%)   2.1*   6.6*   2.4*   7.6* 
   Rheumatologic disease (%)   5.9   7.2   6.3   6.6 
   Chronic pulmonary disease (%) 34.5* 54.6* 35.4* 60.4* 
   Liver disease (%)   1.0   2.0   1.0   3.0 
   Cancer (%) 28.3 32.9 27.7 36.8 
   Cancer with metastasis (%)   6.6   9.2   6.8   9.4 
   Diabetes (%) 26.2 32.2 28.0 29.2 
   Diabetes with complications (%)   3.8   5.9   3.9   6.6 
   Paralysis (%)   0.3   2.0   0.3   2.8 
   AIDS (%)   1.0   1.3   0.9   1.9 
   Renal disease (%)   3.8*   9.2*   3.9* 11.3* 
   Aneurysm (%)   5.2   8.6   6.2   6.6 
   Gangrene (%)   0.3   1.3   0.3   1.9 
Prescription Drug Utilization 
    
Average no. of dispensings (SD)   9.0 (7.1) 10.3 (7.2)   9.1 (7.1) 10.5 (7.3) 
Pct with ≥ 1 dispensing 87 93 88 92 
Medical Care Utilization 
    
Average no. IP days (SD)3   1.7 (3.9)*   5.5 (11.7)*   1.8 (4.1) *   6.8 (13.3) * 
Average no. IP stays (SD)   0.3 (0.6)   0.8 (1.0)   0.3 (0.6)   0.9 (1.1) 
Average length of IP stays (SD)4   5.4 (4.8)   6.8 (5.5)   5.7 (5.1)   6.7 (5.2) 
Average no. of OP visits (SD)   6.0 (8.5)   4.9 (8.7)   6.0 (8.6)   4.5 (8.6) 
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Pct with ≥ 1 OP visit 82* 66* 81* 63* 
Average ≥ 1 ED visit  (SD)   0.5 (0.9)*   0.8 (1.3)*   0.5 (1.0)*   0.9 (1.3) * 
Pct with ≥ 1 home health claim 23.1* 40.1* 24.7* 42.4* 
Pct with ≥ 1 ambulatory surgery claim   3.8   2.0   3.6   1.9 
Pct with ≥ 1 rehabilitation/SNF claim   3.1   5.3   3.3   5.7 
Pct with ≥ 1 DME claim5   6.9* 21.7*   8.0* 24.5* 
 
 
1
 Pre 2009: Good PS = ECOG: 0 – 1; KPS: 80 – 100; Poor PS = ECOG: 2 – 5; KPS: 0 – 70. 
2 Post 2009: Good PS = ECOG: 0 – 2; KPS: 60 – 100; Poor PS = ECOG: 3 – 5; KPS: 0 – 50.  
3 Among all patients (including those with no inpatient stays). 
4 No. of inpatient days divided by no. of inpatient stays – among patients with at least one 
inpatient stay. 
5 DME included claims for portable oxygen, walkers, canes, wheelchairs, and hospital beds. 
*
 Significant difference at 5% level.  
Abbreviations: standard deviation (SD); percent (Pct); number (no.); American Joint Committee 
on Cancer (AJCC); inpatient (IP); outpatient (OP); emergency department (ED); skilled nursing 
facility (SNF); durable medical equipment (DME).  
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Table 4. Estimated Logistic Regression Parameters (β) and Standard Errors (SE) 
and Measures of Model Performance for Alternative Models of Performance 
Status Predictors 
 
PS (Pre 2009): Good/Poor1 Model 1 Model 2 Model 3 
Variable β SE β SE β SE 
Intercept  3.97 0.85***  3.65 0.94***  4.55 1.03*** 
Age in years at diagnosis -0.04 0.01** -0.04 0.01** -0.04 0.01** 
AJCC Stage IV -0.84 0.21*** -0.81 0.23** -0.84 0.23** 
Chronic pulmonary disease   -0.67 0.24** -0.63 0.24** 
Number of Inpatient Stays   -0.58 0.16** -0.60 0.16** 
Any number of outpatient 
visits 
   1.05 0.26***  1.19 0.27*** 
Number of ED visits   -0.22 0.10* -0.22 0.10* 
Any number of DME claim   -0.80 0.35* -0.81 0.36* 
Any prescription drug 
dispensing 
  -1.08 0.43* 
     
Model Performance     
C statistic (95% CI) 0.66 (0.61, 0.71) 0.75 (0.71, 0.81) 0.76 (0.72, 0.81) 
R2 (95% CI) 0.07 (0.03, 0.11) 0.19 (0.13, 0.26) 0.20 (0.15, 0.28) 
    
Predictive Threshold = 0.50    
Sensitivity (95% CI) 0.88 (0.78, 1.00) 0.90 (0.84, 0.94) 0.88 (0.84, 0.93) 
Specificity (95% CI) 0.20 (0.00, 0.40) 0.43 (0.31, 0.55) 0.45 (0.34, 0.56) 
False positive (95% CI) 0.32 (0.28, 0.37) 0.25 (0.21, 0.29) 0.25 (0.20, 0.29) 
False negative (95% CI) 0.54 (0.29, 0.87) 0.31 (0.24, 0.40) 0.34 (0.25, 0.40) 
    
Predictive Threshold = 0.60    
Sensitivity (95% CI) 0.72 (0.61, 0.83) 0.79 (0.72, 0.87) 0.79 (0.72, 0.87) 
Specificity (95% CI) 0.43 (0.27, 0.65) 0.53 (0.45, 0.66) 0.55 (0.47, 0.67) 
False positive (95% CI) 0.29 (0.23, 0.33) 0.24 (0.18, 0.27) 0.23 (0.18, 0.26) 
False negative (95% CI) 0.55 (0.46, 0.62) 0.43 (0.34, 0.49) 0.42 (0.34, 0.48) 
    
Predictive Threshold = 0.70    
Sensitivity (95% CI) 0.49 (0.33, 0.65) 0.61 (0.52, 0.74) 0.64 (0.53, 0.75) 
Specificity (95% CI) 0.75 (0.60, 0.88) 0.69 (0.60, 0.79) 0.69 (0.61, 0.79) 
False positive (95% CI) 0.21 (0.16, 0.26) 0.21 (0.16, 0.25) 0.20 (0.15, 0.25) 
False negative (95% CI) 0.56 (0.51, 0.62) 0.52 (0.44, 0.57) 0.50 (0.43, 0.56) 
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PS (Post 2009): Good/Poor2 Model 1 Model 2 Model 3 
Variable β SE β SE β SE 
Intercept  4.39 0.94***  4.25 1.08***  5.08 1.18*** 
Age in years at diagnosis -0.04 0.01*** -0.04 0.02** -0.04 0.02** 
AJCC Stage IV -0.64 0.23*** -0.55 0.26** -0.57 0.26** 
Chronic pulmonary disease   -0.88 0.27*** -0.83 0.27*** 
Number of Inpatient Stays   -0.80 0.17*** -0.81 0.17*** 
Any number of outpatient 
visits 
   1.08 0.29***  1.20 0.30*** 
Number of ED visits   -0.25 0.11** -0.25 0.11** 
Any number of DME claim   -0.60 0.36* -0.61 0.36* 
Any prescription drug 
dispensing 
  -0.98 0.50* 
     
Model Performance     
C statistic (95% CI) 0.64 (0.58, 0.70) 0.78 (0.74, 0.84) 0.78 (0.74, 0.85) 
R2 (95% CI) 0.04 (0.01, 0.08) 0.19 (0.13, 0.28) 0.20 (0.14, 0.28) 
    
Predictive Threshold = 0.50    
Sensitivity (95% CI) 1.00 (0.98, 1.00) 0.94 (0.91, 0.97) 0.94 (0.91, 0.97) 
Specificity (95% CI) 0.00 (0.00, 0.01) 0.28 (0.19, 0.47) 0.32 (0.21, 0.50) 
False positive (95% CI) 0.24 (0.20, 0.28) 0.19 (0.15, 0.22) 0.19 (0.14, 0.22) 
False negative (95% CI) 1.00 (0.98, 1.00) 0.40 (0.23, 0.48) 0.38 (0.21, 0.46) 
    
Predictive Threshold = 0.60    
Sensitivity (95% CI) 0.96 (0.87, 1.00) 0.90 (0.86, 0.94) 0.90 (0.86, 0.94) 
Specificity (95% CI) 0.06 (0.00, 0.27) 0.42 (0.29, 0.59) 0.45 (0.32, 0.60) 
False positive (95% CI) 0.24 (0.20, 0.27) 0.17 (0.13, 0.20) 0.16 (0.12, 0.20) 
False negative (95% CI) 0.71 (0.37, 1.00) 0.42 (0.32, 0.52) 0.42 (0.32, 0.51) 
    
Predictive Threshold = 0.70    
Sensitivity (95% CI) 0.76 (0.62, 0.91) 0.83 (0.78, 0.99) 0.83 (0.76, 0.88) 
Specificity (95% CI) 0.37 (0.13, 0.63) 0.56 (0.22, 0.72) 0.55 (0.46, 0.70) 
False positive (95% CI) 0.21 (0.16, 0.24) 0.14 (0.11, 0.21) 0.15 (0.10, 0.17) 
False negative (95% CI) 0.67 (0.55, 0.78) 0.49 (0.28, 0.58) 0.50 (0.41, 0.57) 
 
Model 1: Significant (P<0.05) performance status predictors from tumor registries (age at 
diagnosis and AJCC stage). Model 2: Significant performance status predictors from medical 
claims (age at diagnosis, diagnosis of COPD, inpatient stays, any outpatient visits, and 
emergency department visit). Model 3: Significant performance status predictors from tumor 
registries, medical claims, and pharmacy claims (age at diagnosis, AJCC stage, diagnosis of 
COPD, inpatient stays, any outpatient visits, emergency department visit, and any prescriptions). 
*P<0.05; **P<0.01; ***P<0.0001. 
Abbreviations: American Joint Committee on Cancer (AJCC); emergency department (ED); 
durable medical equipment (DME); chronic pulmonary disease (COPD). 
25 
 
 
 
Table 5.  Number of Patients with Observed (Predicted) Good Performance 
Status (PS) by Model and Model Determined Decile 
 
Rank  
Deciles  
Number with Observed (Predicted) Good PS (Pre 2009) 
Model 1 Model 2 Model 3 
     1 23 (21) 10  (9)   8  (8) 
     2 23 (22) 13 (18) 14 (18) 
     3 25 (24) 29 (24) 28 (23) 
     4 26 (27) 29 (27) 27 (27) 
     5 23 (27) 31 (30) 32 (30) 
     6 28 (31) 33 (32) 37 (33) 
     7 26 (29) 34 (34) 31 (36) 
     8 37 (34) 33 (36) 34 (37) 
     9 39 (37) 37 (40) 38 (39) 
    10 40 (38) 41 (40) 41 (39) 
 
   
P value 0.69 0.32 0.13 
 
Rank  
Deciles  
Number with Observed (Predicted) Good PS (Post 2009) 
Model 1 Model 2 Model 3 
     1 28 (28) 12 (12) 10 (12) 
     2 29 (30) 22 (24) 24 (24) 
     3 34 (33) 32 (30) 32 (30) 
     4 37 (36) 33 (33) 34 (33) 
     5 32 (34) 38 (36) 36 (36) 
     6 34 (35) 40 (38) 37 (37) 
     7 39 (37) 35 (38) 39 (39) 
     8 42 (42) 42 (40) 39 (40) 
     9 36 (37) 41 (42) 41 (42) 
    10 25 (23) 41 (41) 44 (43) 
 
   
P value 0.92 0.63 0.98 
 
 
1 Deciles were created by ranking patients according to increasing predicted likelihood of good 
performance status on the basis of the explanatory variables in each of the three models. 
2 Pre 2009: Good PS = ECOG: 0 – 1 or KPS: 80 – 100 / Poor PS = ECOG: 2 – 5 or KPS: 0 – 70. 
3 Post 2009: Good PS = ECOG: 0 – 2 or KPS: 60 – 100 / Poor PS = ECOG: 3 – 5 or KPS: 0 – 50.
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2.4 Discussion 
Among a contemporary cohort of patients with stage II through IV lung 
cancer, explicit medical record documentation of PS was found less than half the 
time (47%). Review of nursing and physician notes led PS to be determinable via 
medical records approximately 80% of the time. Given the central role that PS 
plays in clinical decision-making among patients with lung cancer, the lack of 
consistent medical record documentation is troubling. When documented, we 
found the distribution of PS among the cohort (34% with poor PS [when a PS of 2 
was considered as having poor PS]) to be identical to the 34% with poor PS 
reported by Lilenbaum et al in contemporary clinical studies (R. C. Lilenbaum et 
al. 2008). 
It was found that poor PS among lung cancer patients with stage III to IV 
disease can be predicted reasonably well regardless of whether a PS of 2 is 
considered good or poor. Furthermore, this was true regardless of the level of 
comprehensiveness of the data used, but particularly for models that used 
information routinely available in medical claims data or medical and 
pharmaceutical claims data combined, in which the c statistics were all >0.70. 
Although the inclusion of information routinely available in medical claims data 
marginally improved model fit and predictive accuracy when compared with a 
model fit using only data available in tumor registries, the inclusion of information 
from pharmaceutical claims data did not appear to substantively alter model fit, 
regardless of how good PS is defined. 
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To my knowledge, this is the first study to use observational data to 
estimate PS for lung, or any other, cancer patients. As such, these findings 
represent a significant contribution to the field. These findings are important for 
the ability to monitor quality of care and the appropriateness of chemotherapy, 
and the ability to prospectively identify patients who may be appropriate (but not 
targeted) for clinical trial or palliative care/hospice enrollment without relying on 
expensive and time-consuming primary data collection methods. Predictive 
models such as those presented herein that rely on data routinely available 
within large, observational databases can also be used to augment comparative 
effectiveness research, including comparisons of different chemotherapy 
regimens as well as the receipt of chemotherapy versus non-chemotherapy 
treatment and thereby greatly enhance the capabilities of existing electronic 
databases such as that available via Surveillance, Epidemiology, and End 
Results (SEER)-Medicare data. 
Although these findings of significant differences in chemotherapy receipt 
by good versus poor PS add face validity to the accuracy of the PS score 
abstracted from the medical record, the finding that approximately 42% of 
patients with medical record-documented poor PS received chemotherapy in the 
year after diagnosis highlights the importance of attempts such as ours to make 
documented PS or PS proxies more readily available to those who monitor and 
study cancer care quality and outcomes. At the time of this study, national clinical 
practice guidelines for patients with non-small cell lung cancer unequivocally 
recommended chemotherapy for patients with a PS of 0 or 1 (1997;D. G. Pfister 
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et al. 2004). These guidelines suggested that chemotherapy might ‘‘possibly’’ be 
of benefit in patients with a PS of 2, noting that those patients had been excluded 
from clinical trials. This was in keeping with expert opinions of the time (E. 
Rodriguez, R. C. Lilenbaum 2008). More recent data have shown survival and 
quality of life benefits for patients with a PS of 2, although less than with good 
PS, and the most recent ASCO guidelines are more supportive of chemotherapy 
for patients with a PS of 2 (C. G. Azzoli et al. 2009). Routine chemotherapy 
among lung cancer patients with a PS ≥ 3 continues to not be recommended by 
any national professional organization. Chemotherapy use in patients with little 
chance of benefit and more chance of toxicity may delay discussion about 
prognosis and dying (A. A. Wright et al. 2008), which may lead to further poor 
quality of care, such as the inappropriate use of mechanical ventilation or delays 
in referral to hospice, worse surviving caregiver quality of life, and high end-of-life 
care costs (B. Zhang et al. 2009). Without PS proxies, little can be done to use 
automated data sources to monitor and measure either the underuse or overuse 
of chemotherapy and its implications on patient and economic outcomes. 
The results of the current study should be interpreted in light of the 
following limitations. First, subjectivity is present in the assignment of PS. Even 
when assessed by a healthcare professional, PS scales are subjective in nature 
(K. Kelly 2004) and when estimated by physicians are known to be prone to error 
(C. Zimmermann et al. 2010), usually being overestimated (R. C. Lilenbaum et al. 
2008). Thus, even if this model were 100% accurate, caution would have to be 
used in interpreting results dependent on an accurate classification of PS. 
29 
 
 
 
Nonetheless, the ability to develop a useful proxy measure of PS from existing 
observational data will help in the use of existing national data resources such as 
that available with SEER Medicare data for comparative effectiveness research. 
Second, these models were developed on a relatively small sample and one that 
is specific to 1 delivery system. Therefore, not only should care be taken when 
generalizing findings, but the parsimonious models may exclude important 
predictors of PS available in observational data. Finally, identifying patients with 
poor PS by their diagnoses and use of care via claims data poses its own 
limitations. For example, DME use varies significantly based on differing personal 
preferences and practices in addition to restrictions on reimbursement by public 
and private insurers. Although claims for DME offer useful information, they 
identify only selected people with potentially disabling conditions (L. I. Iezzoni 
2003). The same is true of medical diagnoses, many of which are known to be 
under captured in medical claims data, and prescription drug dispensing, which 
reflects only those medications prescribed by physicians that the patient elected 
to fill. Nevertheless, the ability to proxy PS is critical to the ability to use 
observational data to accurately draw conclusions regarding comparative 
effectiveness and cancer care quality at a population level if not at the bedside. 
Despite these limitations, results from the current study shed new light on 
the capacity of information routinely available in observational data to identify 
lung cancer patients with good versus poor PS. This is especially useful for 
researchers interested in leveraging existing observational databases for 
comparative effectiveness research. Recent studies have highlighted a likely 
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overuse of chemotherapy in the treatment of patients with lung cancer as well as 
aggressive treatment near the end of life (C. C. Earle et al. 2004;R. Matsuyama 
et al. 2006;S. E. Harrington, T. J. Smith 2008). Using a predictive model such as 
the one developed herein with a threshold of 0.70 to proxy a patient as having 
poor PS would ensure reasonably high specificity (0.69 if a PS of 2 is considered 
poor) and thereby enable the identification of a population for whom the receipt of 
chemotherapy appears inadvisable or requiring a more tailored discussion of less 
benefit and more risk per current guideline recommendations, and for whom 
early hospice intervention may be warranted. Conversely, using a lower 
predictive threshold (0.50) and thereby increasing the sensitivity of the predictive 
model may be useful to health disparities researchers, in whom interest might be 
in testing a hypothesis centered on under treatment among minority populations. 
Similarly, choosing a predictive threshold with a high sensitivity could facilitate 
population identification for observational comparative effectiveness research. 
The best selection of both a predictive threshold and the allocation of patients 
with a PS of 2 will ultimately depend on the user’s objectives. 
PS has long been considered one of the strongest prognostic factors (K. 
S. Albain et al. 1991) and is used today by clinicians to assess the 
appropriateness of chemotherapy and regimen choice for patients with lung 
cancer (C. G. Azzoli et al. 2009). With the aging population, the number of 
Americans with functional limitations will increase dramatically, and therefore the 
urgency to capture and classify information regarding functional status will grow 
(L. I. Iezzoni, M. S. Greenberg 2003). Furthermore, given the current challenges 
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faced by the US healthcare system to deliver better and more cost-effective 
outcomes, the importance of comparative effectiveness studies is likely to only 
grow. To the best of my knowledge, the results of the current study are the first to 
provide health services researchers and others with a viable tool with which to 
predict PS among lung cancer patients using information routinely available in 
observational data. As such, the value of observational data for comparative 
effectiveness research and for use by those interested in understanding cancer 
care quality or targeting specific lung cancer patients for possible inclusion in 
clinical trials, hospice care, or other interventions is greatly enhanced. 
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CHAPTER 3. FACTORS ASSOCIATED WITH ADHERENCE TO 
CHEMOTHERAPY GUIDELINES IN PATIENTS WITH LUNG 
CANCER 
 
Evidence-based guidelines recommend chemotherapy for medically fit 
patients with stage II-IV non-small cell lung cancer (NSCLC). Adherence to 
chemotherapy guidelines has rarely been studied among large populations, 
mainly because performance status (PS), a key component in assessing 
chemotherapy appropriateness, is missing from claims-based or other automated 
datasets. Among a large cohort of patients with known PS, chemotherapy use is 
described relative to guideline recommendations and patient factors associated 
with guideline concordant use are identified.  
Insured patients, ages 50+, diagnosed with stage II-IV NSCLC between 
2000-2007 were identified via tumor registry (n=406). Chart abstracted PS, 
automated medical claims, Census tract information, and travel distance were 
linked to tumor registry data. Chemotherapy was appropriate for patients with PS 
0-2. Multivariate logit models were fit to evaluate patient characteristics 
associated with chemotherapy over- and under-use per guideline 
recommendations. 
Overall compliance with chemotherapy guidelines was 71%. Significant 
(p<0.05) predictors of chemotherapy underuse (19%) included increasing age 
(odds ratio [OR], 1.09), higher income (OR, 1.02), diagnosed before 2003 (OR, 
2.05), and vehicle access (OR, 6.96) in the patient’s neighborhood. Significant 
predictors of chemotherapy overuse (10%) included decreasing age (OR, 0.92), 
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diagnosed after 2003 (OR, 3.24), and higher income (OR, 1.05) in the patient’s 
neighborhood. 
Among NSCLC patients 29% do not receive guideline recommended 
chemotherapy treatment, missing opportunities for cure or receiving 
chemotherapy with more risk of harm than benefit, thereby likely foregoing 
beneficial palliation. Care concordant with guidelines is influenced by age, and 
economic considerations, such as income, and transportation barriers.    
 
3.1 Introduction 
Evidence-based treatment guidelines recommend the use of 
chemotherapy for medically fit patients with unresectable or stage IV non-small 
cell lung cancer (NSCLC) to improve survival, symptoms, and quality of life 
(1997;2010b;D. G. Pfister et al. 2004;2010c). Despite these recommendations, 
studies in the past decade have documented variability in the receipt of 
chemotherapy among patients with NSCLC (T. J. Smith et al. 1995;P. B. Bach et 
al. 1999;C. C. Earle et al. 2000;A. L. Potosky et al. 2004). Understanding the 
extent to which chemotherapy use in practice is consistent with these guidelines, 
as well as the factors associated with inappropriate chemotherapy use has rarely 
been studied among large populations, mainly because performance status (PS), 
a key clinical component in assessing chemotherapy appropriateness, is typically 
missing from claims-based databases.  
Determining whether care meets professional standards is important in 
lung cancer care.  Adherence to evidence-based guidelines has been used to 
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assess the quality of health care for a wide range of conditions (M. A. Schuster et 
al. 2005), so it is natural to ask how often lung cancer care agrees with guideline 
recommended care. Previous studies suggest that chemotherapy is sometimes 
overused at the end of life, with 20% (C. C. Earle et al. 2004) to 43% (J. R. 
Murillo, Jr., J. Koeller 2006) or more of lung cancer patients receiving 
chemotherapy within just a few weeks of a patient’s death. Yet, lung cancer 
patients who use hospice for at least one day – thus avoiding chemotherapy 
during their stay in hospice, and getting appropriate symptom management – 
have been shown to live significantly longer than lung cancer patients who never 
use hospice.(S. R. Connor et al. 2007) Recent studies show that at 2 months 
before their death, half of the doctors of lung cancer patients have not even 
mentioned hospice options (H. A. Huskamp et al. 2009), and the average 
hospice length of stay is only 4 days (J. S. Temel et al. 2010). At the same time, 
an underuse of curative surgery, combined chemotherapy and radiation (P. B. 
Bach et al. 1999;T. J. Smith et al. 1995) and palliative chemotherapy may 
unnecessarily increase the symptom burden and the death rate from this 
disease. 
 The issue of guideline adherence has been more comprehensively 
examined in breast cancer research where a number of studies have 
demonstrated improvement in survival when patients were treated according to 
clinical practice guidelines (A. Olivotto et al. 1997;N. Hebert-Croteau et al. 
2004;T. L. Lash et al. 2000;T. L. Lash et al. 2005). Several breast cancer studies 
have found that increased age, comorbidity, black race, lower educational 
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attainment, and advanced disease stage are associated with receipt of 
nonstandard treatment regimens (usually underuse or use of reduced doses), 
which in turn contributes to less favorable outcomes (J. J. Griggs et al. 2007;N. 
A. Bickell et al. 2006;D. Hershman et al. 2005;N. A. Bickell et al. 2009;N. Krieger 
1992). Furthermore, a conceptual model that explains the underuse of effective 
therapy in breast cancer has been proposed, where therapy underuse is 
explained by the interaction of patient, physician, and system factors, each of 
which exists within a health care system and an individual’s community (N. A. 
Bickell 2002).  
 The purpose of this research is to quantify the extent of adherence to 
evidence-based guidelines for use of chemotherapy among an insured 
population diagnosed with NSCLC between 2000 and 2007 with medical record 
documented PS, and to evaluate the factors associated with both the under- and 
over-use of chemotherapy within this cohort.  By combining data from patients’ 
medical records with those available via an automated tumor registry, medical 
claims, and Census data, this study is able to consider the patients’ clinical and 
socio-demographic characteristics, as well as the characteristics of the 
neighborhood in which they reside and how they are associated with use 
consistent with guidelines. 
 Studies of chemotherapy use for NSCLC in the past have neglected PS, a 
clinically important measure in the assessment of appropriateness of 
chemotherapy. The present study contributes to the literature by explicitly 
accounting for a patient’s PS. In so doing, it is able to accurately quantify the 
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extent and nature of deviations from treatment guidelines, and to quantify the 
patient characteristics associated with both under- and overuse of chemotherapy.     
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3.2 Methods 
Study Population and Setting  
Study patients were those receiving care from a 900-physician member, 
multispecialty, salaried medical group practice in southeast Michigan. Data 
available from the medical group’s tumor registry were used to identify all 
patients aged ≥ 50 years who were diagnosed with NSCLC between January 1, 
2000 and December 31, 2007. The medical group, which provides care under 
both fee-for-service and capitated arrangements, staffs 27 primary care clinics 
throughout Detroit and the surrounding metropolitan area. Patients eligible for 
study inclusion were those continuously enrolled in an affiliated health plan (ie, 
health maintenance organization) for the 1-year period preceding their date of 
lung cancer diagnosis. Patients for whom no stage of disease was available or 
for whom the stage at diagnosis was 0 or I were excluded.  The latter were 
excluded because chemotherapy was not indicated for patients with stage 0 or I 
disease during this time period (W. J. Scott et al. 2007). Patients who died within 
one month of their diagnosis were also excluded from the study. The medical 
group’s Institutional Review Board approved all aspects of the study protocol. 
 
Primary Outcome of Interest  
Per the American Society of Clinical Oncology (ASCO) clinical practice 
guidelines issued in 2009 (C. G. Azzoli et al. 2009), chemotherapy was 
recommended for patients with good PS (i.e., PS= 0-2) and not recommended for 
patients with poor PS (i.e., PS=3-4). Earlier ASCO guidelines had recommended 
38 
 
 
 
chemotherapy for patients with PS 0-1 only.(1997) In model estimations I include 
patients with PS=2 in the good PS group. Alternative models that instead include 
PS 2 patients in the poor PS group were also estimated, and are included in 
Appendix A. Throughout, instances in which patients with good PS did not 
receive chemotherapy were classified as “underuse,” while instances in which 
patients with poor PS received chemotherapy were classified as “overuse.”   
Two trained chart abstractors reviewed inpatient and outpatient nursing 
and physician notes available within the patient’s electronic medical record from 
2 months before diagnosis until the first notation of death, disenrollment, initiation 
of chemotherapy, or 6 months after diagnosis to obtain PS. Abstractors 
documented specific numeric PS, if available, or an estimated PS based on 
medical notes. In the latter case, notes regarding the patient’s functionality (e.g., 
references to shortness of breath, use of a wheelchair or other personal mobility 
devices, labor force participation, exercising habits, activities of daily living, or 
other references to mobility) were recorded and used to estimate PS. Inter-rater 
reliability between the 2 abstractors was assessed on a random subset of 40 
observations and the resulting Cohen κ was 0.88.  
 
Automated Tumor Registry and Claims Data 
Automated tumor registry and claims data were accessed to obtain patient 
demographic characteristics, date of cancer diagnosis, stage at diagnosis, and 
comorbidities in the 12-month period preceding diagnosis for each patient. 
Patient demographics included age, gender, and race. The age of the patient (in 
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years) was recorded as of the date of lung cancer diagnosis. Clinical measures 
for each patient included stage of disease at the time of diagnosis and the 
Charlson comorbidity index (M. E. Charlson et al. 1987). Cancer stage was 
reported using the American Joint Committee on Cancer (AJCC) stages II 
through IV. The Deyo adaptation of the Charlson comorbidity index and each of 
its component diagnostic subgroups were constructed using inpatient and 
outpatient diagnostic information available in the 12-month period preceding 
diagnosis (R. A. Deyo et al. 1992).  
 
Socioeconomic Data  
Socioeconomic information, including education level, median household 
income, and vehicles per household were obtained from the 2000 US Census.  
Using patients’ residential street address, Census tract level data were used to 
characterize the socioeconomic profile of each patient’s neighborhood of 
residence.  MapPoint (2010; Microsoft Corporation, Redmond, WA) was used to 
calculate the travel distance between each patient’s home and the nearest 
chemotherapy facility that was affiliated with the group practice.  
  
Statistical Analysis 
Patients were assigned into 4 distinct groups: patients with good PS who 
received chemotherapy; patients with good PS who did not receive 
chemotherapy; patients with poor PS who received chemotherapy; and patients 
with poor PS who did not receive chemotherapy. Systematic unadjusted 
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differences between patients receiving chemotherapy and those who did not 
receive chemotherapy, within the good PS and poor PS groups (patients in the 
first two groups and patients in the latter two groups) were examined, using 2-
sample Student t tests (or Wilcoxon rank sum tests) and chi-square tests, 
depending on the nature of the characteristic. Two multivariate logistic regression 
models were fit to evaluate the factors associated with receipt of chemotherapy, 
given the patient’s PS. The first model estimated chemotherapy receipt among 
patients with good PS (i.e., evaluated factors associated with chemotherapy 
under use) while the second model estimated chemotherapy receipt among 
patients with poor PS (i.e. evaluated factors associated with chemotherapy 
overuse). Both models controlled for patient age at diagnosis, gender, race, and 
comorbidities as well as the college graduation rate, median household income, 
and vehicle access in their neighborhood, distance to nearest chemotherapy 
facility, and year of diagnosis.  
SAS statistical software (version 9.1.3; SAS Institute Inc, Cary, NC) was 
used for all analyses. P < .05 was considered to be statistically significant.  
 
3.3 Results 
Cohort Characteristics 
A total of 406 patients met the criteria for study eligibility. Overall sample 
characteristics are reported in Table 6. The mean age of the cohort was 67.4 
years (standard deviation [SD], 8.9 years). Just under half (41%) were female, 
whereas the racial distribution was 69% white, 29% black, and 2% of other races. 
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The AJCC staging distribution was as follows: 11% of patients were diagnosed 
with stage II disease, 41% were diagnosed with stage IIII disease, and 48% were 
diagnosed with stage IV disease. The average Charlson comorbidity index 
across the sample was 1.3 (SD, 1.6). 
 At the Census tract level, the mean college graduation rate for the cohort 
was 6.9% (SD, 5.6), the median household income (in 2000) was $49,200 (SD, 
21,900), and 12.2% (SD, 19.0) of residents lived in households that had no 
vehicles. The average travel distance of patients to the nearest chemotherapy 
facility was 10.8 miles (SD, 11.7).  
Across the sample, 13% of patients received no anti-cancer treatment for 
their lung cancer, 1% received surgery only, 16% received radiation therapy only, 
13% received chemotherapy only, 5% received a combination of surgery and 
chemotherapy but no radiation, 44% received radiation and chemotherapy but no 
surgery, and 8% received all three modes of treatment.  
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Table 6. Overall Sample Characteristics, Lung Cancer Patients with Stages II-IV 
(n = 406) 
 
Demographic Characteristics  
  Average age at diagnosis (SD) 67.4 (8.9) 
  Gender (%)  
          Female  41 
          Male  59 
  Race (%)  
          Black 29 
          White 69 
          Other   2 
Clinical Characteristics  
  AJCC stage (%)  
          II 11 
          III 41 
          IV 48 
  Average Charlson comorbidity index (SD)   1.3 (1.6) 
Socioeconomic Characteristics  
  Pct with college degree (SD)   6.9 (5.6) 
  Median household income in $1000s (SD) 49.2(21.9) 
Access to Treatment  
  Pct without vehicle (SD) 12.2(19.0) 
  Distance (miles) to chemotherapy facility (SD) 10.8(11.7) 
Treatment(s) Received  
  No treatment (%) 13 
  Surgery only (%)   1 
  Radiation therapy only (%) 16 
  Chemotherapy only (%) 13 
  Surgery + radiation therapy (%)   0 
  Surgery + chemotherapy (%)   5 
  Radiation + chemotherapy (%) 44 
  Surgery + radiation + chemotherapy (%)   8 
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Chemotherapy Receipt by Performance Status 
Table 7 reports chemotherapy receipt by stage and PS. Overall, 77 
patients (19%) with good PS did not receive chemotherapy, while 39 patients 
(10%) with poor PS received chemotherapy. Among patients diagnosed with 
stage II disease, 9 (20%) with good PS did not receive chemotherapy and 6 
(14%) with poor PS received it. Among those diagnosed with stage III disease, 
31 (19%) with good PS did not receive chemotherapy and 9 (5%) with poor PS 
received it. Among those diagnosed with stage IV disease, 37 (19%) with good 
PS did not receive chemotherapy and 24 (12%) with poor PS received it.   
 Table 8 reports the unadjusted differences in cohort characteristics 
between patients receiving chemotherapy and those not receiving it, across 2 
groups: patients with good PS and poor PS. Among patients with good PS, there 
were significant differences between those receiving chemotherapy and those 
not receiving it by age at diagnosis, the patient’s Charlson comorbidity index, and 
the vehicle ownership rate in the patient’s neighborhood. Among patients with 
poor PS, there were significant differences between those receiving 
chemotherapy and those not receiving it by age and median household income in 
the patient’s neighborhood. 
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Table 7. Chemotherapy Receipt by Performance Status (PS), (N = 406) 
 
 
Chemotherapy 
Received? 
 Yes No 
All Cases, (N = 406) 
ECOG PS 
0-1 213(52%)  63 (16%) 
2 30 (7%) 14 (3%) 
3-4 39 (10%) 47 (12%) 
Stage II, (N = 44) 
ECOG PS 
0-1 25 (57%) 9 (20%) 
2 1 (2%) 0 (0%) 
3-4 6 (14%) 3 (7%) 
Stage III, (N = 165) 
ECOG PS 
0-1 99 (60%) 25 (15%) 
2 8 (5%) 6 (4%) 
3-4 9 (5%) 18 (11%) 
Stage IV, (N = 197) 
ECOG PS 
0-1 89 (45%) 29 (15%) 
2  21 (11%)      8 (4%) 
3-4 24 (12%) 26 (13%) 
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Table 8. Sample Characteristics, by Performance Status (PS) and Choice of 
Chemotherapy Receipt or Non-Receipt, for Lung Cancer Stages II-IV (n = 406) 
 
 Good PS1 (n = 320) Poor PS2 (n = 86) 
Chemo 
(n = 243) 
No Chemo 
(n = 77) 
Chemo 
(n = 39) 
No Chemo 
(n = 47) 
Demographic Characteristics     
  Average age at diagnosis (SD) 65.5 (8.5)3 71.4 (8.9)3 66.9 (9.0)4 71.1 (7.5)4 
  Gender (%)     
          Female  41 47 36 36 
          Male  59 53 64 64 
  Race (%)     
          Black 26 30 31 36 
          White 72 66 69 58 
          Other   2   4   0   6 
Clinical Characteristics     
  AJCC stage (%)     
          II 11 12 15   6 
          III 44 42 23 39 
          IV 45 48 62 55 
  Average Charlson comorbidity index (SD)   1.0 (1.4)3   1.4 (1.5)3   1.9 (2.0)   2.3 (2.3) 
Socioeconomic Characteristics     
  Pct with college degree (SD)   7.1 (6.0)   6.1 (4.9)   6.7 (5.9)   6.9(4.4) 
  Median household income in $1000s (SD) 50.4(22.2)  47.6(19.8) 52.4(27.8)4 42.7(16.6)4 
Access to Treatment     
  Pct without vehicle (SD) 10.0(15.1)3 15.9(21.8)3 12.8(17.7) 16.3(29.3) 
  Distance (miles) to chemotherapy facility 
(SD) 
11.3(13.6) 10.6 (8.7)   9.5 (8.0)   9.6 (6.4) 
Treatment(s) Received     
  No treatment (%)    - 42    - 45 
  Surgery only (%)    -   5    -   2 
  Radiation therapy only (%)    - 52      - 53 
  Chemotherapy only (%) 17    - 31    - 
  Surgery + radiation therapy (%)    -   1    -    - 
  Surgery + chemotherapy (%)   8    -    -    - 
  Radiation + chemotherapy (%) 62    - 64    - 
  Surgery + radiation + chemotherapy (%) 13    -   5    - 
 
                                                 
1
 Good PS: ECOG 0-2 
2
 Poor PS: ECOG>2 
3
 Among patients with good PS, significant difference by chemotherapy receipt/non-receipt, at 5% 
level  
4
 Among patients with poor PS, significant difference by chemotherapy receipt/non-receipt, at 5% 
level 
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Factors Associated with the Non-Receipt of Chemotherapy among Patients 
with Good Performance Status 
Results from the multivariable logistic regression model for factors 
associated with the non-receipt of chemotherapy among patients with good PS 
are presented in Table 9.  As indicated in the model, patients who are 
significantly less likely to receive chemotherapy when the PS is good include 
older patients, patients residing in neighborhoods with higher median household 
income, and those living in neighborhoods with a higher percentage of 
households without any vehicle.  At the same time, patients who are more likely 
to receive chemotherapy when their PS is good include patients residing in 
neighborhoods with a higher percentage of college graduates and patients 
diagnosed in 2003 or later. Factors that were not significant in this model 
included gender, race, comorbidities, and distance to nearest chemotherapy 
facility. 
 
Factors Associated with the Receipt of Chemotherapy among Patients with 
Poor Performance Status 
Table 10 reports the results of the logistic regression model for 
chemotherapy receipt among patients with poor PS. Factors that were 
associated with significantly higher odds of chemotherapy receipt when PS is 
poor include median household income and being diagnosed in 2003 or later. 
Older patients and those who lived in neighborhoods with a higher percentage of 
college graduates are less likely to receive chemotherapy when they have poor 
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PS. Factors that were not significant in this model included gender, race, 
comorbidities, vehicle access, and distance to nearest chemotherapy facility. 
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Table 9. Factors Associated with Non-Receipt of Chemotherapy among Patients 
with Good Performance Status (PS), for Lung Cancer Stages II-IV (N = 320) 
 
Performance Status = Good1 Odds of Under Use (95% CI) P Value 
Patient Demographics   
  Age at diagnosis (years) 1.09 (1.05-1.13)    <0.01 
  Gender = female 1.35 (0.77-2.37)      0.29 
  Race = white 0.75 (0.36-1.58)      0.46 
Clinical Characteristics   
  Charlson comorbidity index 1.16 (0.96-1.39)      0.13 
Socioeconomic Characteristics   
  College degree 0.93 (0.86-1.00)      0.07 
  Median income ($1000s) 1.02 (1.00-1.04)      0.05 
Access to Treatment   
  Pct without vehicle 6.96(1.00-49.34) 0.05 
  Distance to chemo facility               1.00 (0.99-1.03) 0.50 
Guidelines   
  Year of diagnosis < 2003 2.05 (1.17-3.62) 0.01 
Model Performance   
Pseudo-R2   0.13                             
C-statistic  0.74 
 
                                                 
1
 Good PS: ECOG 0-2 
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Table 10. Factors Associated with Receipt of Chemotherapy among Patients with 
Poor Performance Status (PS), for Lung Cancer Stages II-IV (N = 86) 
 
Performance Status = Poor1 Odds of Over Use (95% CI) P Value 
Patient Demographics  
  Age at diagnosis (years) 0.92 (0.86-0.98)       0.01 
  Gender = female 0.87 (0.32-2.38) 0.79 
  Race = white 0.83 (0.24-2.85) 0.77 
Clinical Characteristics   
  Charlson comorbidity index 1.01 (0.78-1.32) 0.92 
Socioeconomic Characteristics   
  College degree 0.89 (0.78-1.02) 0.08 
  Median income ($1000s) 1.05 (1.01-1.10) 0.02 
Access to Treatment    
  Pct without vehicle 3.41(0.25-46.81) 0.36 
  Distance to chemo facility 0.97 (0.90-1.04) 0.38 
Guidelines   
  Year of diagnosis ≥ 2003 3.24 (1.07-9.85) 0.04 
Model Performance   
  Pseudo-R2   0.19 
  C-statistic  0.75 
                                                 
1
 Poor PS: ECOG>2 
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3.4 Discussion 
Using a large cohort of patients with lung cancer for whom PS is known, 
this study found the overall adherence to evidence-based guidelines for 
chemotherapy treatment to be 71%.  Among those whose care was non-
concordant with guideline recommendations, 19% did not receive chemotherapy 
when it was indicated and 10% received chemotherapy when it was not 
recommended. This study recorded a higher adherence rate than a previous lung 
cancer study that used population-based Medicare data and did not control for 
PS (A. L. Potosky et al. 2004). This study finds that older patients are less likely 
to use chemotherapy, regardless of their PS. That is, among patients with good 
PS, older patients are less likely to receive recommended chemotherapy, and 
among patients with poor PS, they are also less likely to receive chemotherapy.  
While the latter likely implies high quality care, the former does not. Variations in 
the receipt of chemotherapy by age are consistent with findings from a previous 
study (A. L. Potosky et al. 2004). Whether this is a result of patient preferences 
or barriers, physician bias, or a combination of these is not known.   
The higher the median household income in the patient’s neighborhood of 
residence the more likely they are to be out of compliance in both directions, both 
“overusing” and “underusing” chemotherapy. As with the findings of differences in 
chemotherapy use by patient age, this study is not able to determine the extent 
to which observed utilization is a result of patient preferences or barriers, 
physician bias or a combination of these.   
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Unlike other studies that analyzed Medicare claims data, this research 
considered a rarely studied managed care cohort that included younger patients 
as well as older ones. Another notable difference is that this study found no racial 
differences were found in the receipt of chemotherapy (either underuse or 
overuse).  This difference may be attributable to two factors.  First, the study 
population consisted of patients who received their care through a managed care 
plan, whereas previous studies have focused mainly on seniors with traditional 
Medicare (i.e., Parts A and B), not enrolled in a Medicare managed care plan 
(i.e., Part C). Research suggests that managed care plans reduce health care 
disparities, at least for broadly defined measures of access to care (A. I. Balsa et 
al. 2007). Second, unlike prior studies (P. B. Bach et al. 1999;A. L. Potosky et al. 
2004;T. J. Smith et al. 1995), this one was able to control for a patient’s PS as 
well as several socioeconomic characteristics at the census tract level, i.e., 
education, income, and car ownership. It may not be race, per se, that leads to 
previously documented treatment disparities, but rather PS and socioeconomic 
characteristics, both of which are highly correlated with race.  
Finally, among the urban/suburban population studied here, travel 
distance was not found to be associated with recommended chemotherapy 
treatment.  Instead, the study found that if fewer households in a patient’s 
neighborhood had access to a car, this travel barrier was associated with 
underuse of chemotherapy relative to guideline recommendations.  This finding 
implies that even among a non-rural population, the presence of transportation 
barriers is an important predictor of the underuse of chemotherapy among 
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patients with good PS. Thus, despite the health system in which this study was 
conducted having multiple and geographically dispersed clinics that offer 
chemotherapy treatment,  these findings suggest that patients without access to 
a car may have difficulty reaching a clinic, even when there is a clinic a relatively 
short distance from their home.  
The results of the current study should be interpreted in light of the 
following limitations. First, these findings are based on a cohort of insured cancer 
patients, and adherence rates as well as the factors associated with them may 
differ among an uninsured population.  Similarly, models were developed on a 
sample of patients receiving their care from one delivery system located in a 
large urban area. Therefore, care should be taken when generalizing findings to 
other delivery settings and locales. Likewise, models may exclude important 
factors associated with chemotherapy receipt including provider characteristics 
and variations across health systems and geographical regions. However, the 
average age and other characteristics of this cohort are similar to the whole U.S. 
Finally, this study was not intended to assess appropriateness of specific 
chemotherapy regimens, and further, it is not known whether chemotherapy was 
given with good intent in lieu of hospice for palliative reasons to those with poor 
PS, and if there was any subsequent impact on symptom burden or 
hospitalizations for side effects.  
In summary, about 71% of patients in an insured population received 
chemotherapy concordant with guideline recommendations based on 
performance status, but 29% did not. There will be over 222,000 people 
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diagnosed in the U.S. with lung cancer in 2011 (American Cancer Society 2010). 
Given the effectiveness of modern chemotherapy for palliation and prolonged 
survival, 19% of patients almost certainly did not live as long or as well as they 
might have with chemotherapy, and about 10% of patients received 
chemotherapy that had little chance of benefit and excess risk of toxicity 
including hospitalizations, excess cost, and delay of entry into hospice.  
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CHAPTER 4. ADHERENCE TO CHEMOTHERAPY GUIDELINES 
AND SURVIVAL AMONG PATIENTS WITH LUNG CANCER 
 
Evidence-based guidelines recommend chemotherapy for medically fit 
patients with stage II-IV non-small cell lung cancer (NSCLC). The relationship 
between adherence to chemotherapy guidelines and overall survival is not 
known. Insured patients, ages 50+, diagnosed with stage II-IV NSCLC between 
2000-2007 were identified via tumor registry (n=406). Chart abstracted 
Performance Status (PS), automated medical claims, and Census tract 
information were linked to tumor registry data. Chemotherapy was appropriate for 
patients with PS 0-2. Kaplan Meier estimates were used to describe survival 
differences by PS and choice of chemotherapy. Multivariate Cox logistic 
regression analysis was used to determine the factors associated with treatment 
outcome. 
Guideline adherent use of chemotherapy reduced risk of dying (hazard 
ratio [HR], 0.64). Other factors associated with survival among good PS patients 
(p<0.05) include surgery (HR, 0.33), female gender (HR, 0.66), and stage IV 
disease (HR, 2.19). Overuse of chemotherapy also reduced risk of dying (HR, 
0.04). Among poor PS patients, stage IV diagnosis was also associated with 
higher risk of death (HR, 1.90). Chemotherapy has positive effects on survival for 
both good and poor PS patients. In the poor PS group, the relationship between 
chemotherapy and survival may be affected by other unobservable factors. 
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4.1 Introduction 
Lung cancer is the second most common cancer diagnosed in the United 
States and is the leading cause of cancer-related deaths, with an estimated 
222,520 new cases and 157,300 deaths in 2010. The economic cost of lung 
cancer is high, with an estimated cost of $10 billion per year.(American Cancer 
Society 2010) Non-small cell lung cancer (NSCLC) makes up approximately 85% 
of lung cancer cases in the United States. Because of the incidence, severity, 
and rising costs, it is becoming increasingly important to deliver consistent, high-
quality, cost-effective care for NSCLC. 
Evidence-based treatment guidelines recommend the use of 
chemotherapy for medically fit patients with unresectable or stage IV NSCLC to 
improve survival, symptoms, and quality of life (1997;2010b;2010c;D. G. Pfister 
et al. 2004). Despite these recommendations, studies in the past decade have 
documented variability in the receipt of chemotherapy among patients with 
NSCLC (P. B. Bach et al. 1999;C. C. Earle et al. 2000;A. L. Potosky et al. 
2004;T. J. Smith et al. 1995). 
Due to improvements in surgical techniques and combined therapies, 
survival for lung cancer patients has improved in the last 2 decades. Despite 
these advancements, the 1-year relative survival for lung cancer is just over 40%, 
while the 5-year survival for NSCLC remains at 17%. Although overall survival is 
documented by stage, gender, and other clinical and demographic characteristics 
in studies that have demonstrated significant benefits of chemotherapy (S. D. 
Ramsey et al. 2004;2008), the relationship between adherence to chemotherapy 
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guidelines and survival is not known. This is largely due to the fact that measures 
of PS, a key factor in evaluating the appropriateness of chemotherapy, are 
currently not available though automated medical claims, tumor registries, or 
other observational data commonly used to study cancer treatment and its 
associated outcomes. 
The purpose of this research is to examine survival of insured patients 
diagnosed with NSCLC in relation to adherence to chemotherapy guidelines, 
controlling for other patient clinical and socio-demographic characteristics. By 
combining data from medical records with those available via an automated 
tumor registry, medical claims, Census data, and chart-abstracted PS, this study 
is able to consider the patients’ clinical and socio-demographic characteristics as 
well as adherence to chemotherapy guidelines in measuring effects on survival. 
 
4.2 Methods 
Study Population and Setting 
Study patients were those receiving care from a 900-physician member, 
multispecialty, salaried medical group practice in southeast Michigan. Data 
available from the medical group’s tumor registry were used to identify all 
patients aged ≥ 50 years who were diagnosed with NSCLC between January 1, 
2000 and December 31, 2007. The medical group, which provides care under 
both fee-for-service and capitated arrangements, staffs 27 primary care clinics 
throughout Detroit and the surrounding metropolitan area. Patients eligible for 
study inclusion were those continuously enrolled in an affiliated health plan (ie, 
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health maintenance organization) for the 1-year period preceding their date of 
lung cancer diagnosis. Patients for whom no stage of disease was available or 
for whom the stage at diagnosis was 0 or I were excluded. The latter were 
excluded because chemotherapy was not indicated for patients with stage 0 or I 
disease during this time period (W. J. Scott et al. 2007). Patients who died within 
one month of their diagnosis were also excluded. The medical group’s 
Institutional Review Board approved all aspects of the study protocol. 
 
Performance Status (PS) and Guideline Adherence 
Instances in which patients with good PS did not receive chemotherapy 
were classified as “underuse,” while instances in which patients with poor PS 
received chemotherapy were classified as “overuse.”  Per the American Society 
of Clinical Oncology (ASCO) clinical practice guidelines issued in 2009 (C. G. 
Azzoli et al. 2009), chemotherapy was recommended for patients with good PS 
(i.e., PS= 0-2) and not recommended for patients with poor PS (i.e., PS=3-4). 
Earlier ASCO guidelines had recommended chemotherapy for patients with 
PS=0-1 only.(1997) The baseline models included patients with PS=0-2 in the 
good PS group. Alternative models that considered PS=2 patients with the poor 
PS group were also evaluated. Two trained chart abstractors reviewed inpatient 
and outpatient nursing and physician notes available within the patient’s 
electronic medical record from 2 months before diagnosis until the first notation 
of death, disenrollment, initiation of chemotherapy, or 6 months after diagnosis to 
obtain PS. Abstractors recorded the PS documented closet to the diagnosis date.  
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If no specific PS was documented, they estimated PS based on medical notes. In 
the latter case, notes regarding the patient’s functionality (e.g., references to 
shortness of breath, use of a wheelchair or other personal mobility devices, labor 
force participation, exercising habits, activities of daily living, or other references 
to mobility) were recorded and used to estimate PS. Inter-rater reliability between 
the 2 abstractors was assessed on a random subset of 40 observations and the 
resulting Cohen κ was 0.88.  
 
Automated Tumor Registry and Claims Data 
Automated tumor registry and claims data were accessed to obtain patient 
demographic characteristics, date of cancer diagnosis, stage at diagnosis, and 
comorbidities in the 12-month period preceding diagnosis for each patient. 
Patient demographics included age, gender, and race. The age of the patient (in 
years) was recorded as of the date of lung cancer diagnosis. Clinical measures 
for each patient included stage of disease at the time of diagnosis and the 
Charlson comorbidity index (M. E. Charlson et al. 1987). Cancer stage was 
reported using the American Joint Committee on Cancer (AJCC) stages II 
through IV. The Deyo adaptation of the Charlson comorbidity index and each of 
its component diagnostic subgroups were constructed using inpatient and 
outpatient diagnostic information available in the 12-month period preceding 
diagnosis (R. A. Deyo et al. 1992). The date of death was obtained from the 
tumor registry. 
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 Claims data were also used to identify treatment types, including receipt of 
chemotherapy, surgery, and/or radiation therapy. Because NSCLC has a very 
high short-term mortality rate, initial treatment (chemotherapy, surgery, or 
radiation therapy) was defined by administrative claims codes for these 
treatments appearing within 1 week before, to 3 months after the date of 
diagnosis. 
 
Socioeconomic Data 
 Socioeconomic information included education level and median 
household income. These were obtained from the 2000 US Census using the 
patients’ residential street address. Census tract level data were used to 
characterize the socioeconomic profile of each patient’s neighborhood of 
residence. 
 
Statistical Analysis 
 Patients were assigned into 4 distinct groups: patients with good PS who 
received chemotherapy; patients with good PS who did not receive 
chemotherapy; patients with poor PS who received chemotherapy; and patients 
with poor PS who did not receive chemotherapy. Systematic unadjusted 
differences between patients receiving chemotherapy and those who did not 
receive chemotherapy, within the good PS and poor PS groups (patients in the 
first two groups and patients in the latter two groups) were examined, using 2-
60 
 
 
 
sample Student t test (or Wilcoxon rank sum tests) and chi-square tests, 
depending on the nature of the characteristic.  
 For survival analyses, conventional two-stage instrumental variable 
methods may produce biased estimates in nonlinear models, and two-stage least 
squares regression fails to account for time to death and disregards censoring. 
Therefore, the two-stage residual inclusion (2SRI) method was used to account 
for the endogeneity of chemotherapy receipt in estimating outcomes. Terza et al 
(J. V. Terza et al. 2008). showed that 2SRI estimation is consistent across a 
variety of nonlinear models, including survival models. In the first stage, logistic 
equations were used to evaluate the factors associated with receipt (or non-
receipt) of chemotherapy (Y). Two distinct models were used for the good PS 
and the poor PS groups, as described in chapter 3: 
 
P(Yg=1|X) = exp(Z)/[1+exp(Z)]  for: PS=good 
and     P(Yp=1|X) = exp(Z)/[1+exp(Z)]  for: PS=poor 
 
where Z = β0 +X1β1 + X2β2 + X3β3 + X4β4 + X5β5 + e with each patient having 
demographic covariates (X1), clinical characteristics (X2), socioeconomic 
characteristics (X3), access to treatment (X4), and year of diagnosis (X5). The 
residuals were calculated by subtracting the predicted likelihood of receiving 
chemotherapy from the actual value of the treatment received. Two variables, 
vehicle ownership and the year of diagnosis dummy variable (before/after 2003), 
were identified as instrumental variables in these equations. The first stage 
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residuals were included as additional covariates in the second stage, Cox 
proportional hazards equations, along with the endogenous treatment variables 
and other relevant covariates.  
 
Survival Analysis 
The objective of the survival analysis was to compare survival for patients, 
stratified by PS and receipt of chemotherapy. Patients were initially grouped by 
good vs. poor PS. After stratifying patients by chemotherapy receipt, Kaplan 
Meier survival curves were created. The Kaplan-Meier estimator KM(t) describes 
the probability that the time-to-death T exceeds any given value t. It is plotted as 
a function of t over the range of times of interest and is a decreasing curve with 
value 1 at time of diagnosis and other values given by: 
KM(t) = π (1 - rsi), 
i :si<t 
where {s1, s2, …} are the observed death times and rs is the estimated hazard or 
risk of death at time s, among all patients at risk of death at time s. 
 Cox proportional hazards regression analysis was used to evaluate the 
impact of chemotherapy use by PS group, after adjusting for other relevant 
clinical and socio-demographic characteristics and for the possible endogeneity 
of chemotherapy using residuals from the first-stage logit equations. The Cox 
regression is the most common regression approach used in time-to-event 
problems, and describes the dependence of risk at any time t on the covariates in 
the model (D. R. Cox 1972). It is semi-parametric in that no assumptions are 
made about how the hazard rates vary with time; however, the hazards for 
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different covariate values are assumed to be proportional with a ratio that is 
constant over time. Two multivariate Cox regressions were fit to evaluate survival 
given the patient’s PS:  
 
hg(t|X) = h(t)exp(Xeβe + Xoβo + Xuβu) +e2SRI for: PS=good 
and     hp(t|X) = h(t)exp(Xeβe + Xoβo + Xuβu) +e2SRI for: PS=poor 
 
where Xe is the endogenous regressor (receipt or non-receipt of chemotherapy) 
and Xo is a vector of observable exogenous covariates. In the 2 equations above, 
e2SRI is the regression error term and Xu is the residual from the first-stage model. 
The first model estimated survival among patients with good PS (where 
non-receipt of chemotherapy was considered under use) while the second model 
estimated survival among patients with poor PS (where receipt of chemotherapy 
was considered over use). Both models controlled for the receipt of initial surgery 
and radiation therapy, patient age and AJCC stage at time of diagnosis, gender, 
race, comorbidities, as well as the college graduation rate and median household 
income in their neighborhood.  
 SAS statistical software (version 9.1.3; SAS Institute Inc, Cary, NC) was 
used for all analyses. P < .05 was considered to be statistically significant. 
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4.3 Results 
Cohort Characteristics 
A total of 406 patients met the criteria for study eligibility. Table 11 shows 
the patient characteristics by PS. The mean age of the cohort was 66.9 years 
(standard deviation [SD], 8.9 years) for patients with good PS, compared with 
69.2 years (SD, 8.4) for those with poor PS. Just under half (42%) of good PS 
patients were female versus 36% of poor PS patients, whereas the racial 
distribution for good PS patients was 71% white, 27% black, and 2% of other 
races, compared with 63% white, 34% black, and 3% other races for poor PS 
patients. The AJCC staging distribution was as follows: for good PS, 11% of 
patients were diagnosed with stage II disease, 43% were diagnosed with stage 
IIII disease, and 46% were diagnosed with stage IV disease; for poor PS, 11% of 
patients were diagnosed in stage II, 31% in stage III, and 58% in stage IV. The 
average Charlson comorbidity index across the sample was 1.1 (SD, 1.4) for 
good PS patients and 2.1 (SD, 2.1) for poor PS patients. Of all patients with good 
PS, 63.4% died by the end of the study period and the mean survival was 20.2 
months (SD, 21.4). Poor PS patients experienced significantly poorer survival 
with 84.9% dying by the end of the study period and a mean survival of 10.5 
months (SD, 16.1).  
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Table 11. Overall Sample Characteristics and Survival, Lung Cancer Patients 
with Stages II-IV, by Performance Status (PS) (n = 406) 
 
Demographic Characteristics Good PS 
N = 320 
Poor PS 
N = 86 
  Average age at diagnosis (SD) 66.9 (8.9) 69.2 (8.4) 
  Gender (%)   
          Female  42 36 
          Male  58 64 
  Race (%)   
          Black 27 34 
          White 71 63 
          Other   2   3 
Clinical Characteristics   
  AJCC stage (%)   
          II 11 11 
          III 43 31 
          IV 46 58 
  Average Charlson comorbidity index (SD)   1.1 (1.4)   2.1 (2.1) 
Socioeconomic Characteristics   
  Pct with college degree (SD)   6.9 (5.8)   6.8 (5.1) 
  Median household income in $1000s (SD) 49.7(21.7) 47.1(22.8) 
Treatment(s) Received   
  No treatment (%)   8 28 
  Surgery only (%)   1   1 
  Radiation therapy only (%) 10 31 
  Chemotherapy only (%) 15 11 
  Surgery + radiation therapy (%)   1   0 
  Surgery + chemotherapy (%)   6   0 
  Radiation + chemotherapy (%) 50 27 
  Surgery + radiation + chemotherapy (%)   9   2 
Survival   
   Mean survival time in months (SD) 20.2(21.4) 10.5(16.1) 
   Died by end of study period (%) 63.4 84.9 
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Chemotherapy Receipt by Performance Status 
 Table 12 reports the unadjusted differences in cohort characteristics 
between patients receiving chemotherapy and those not receiving it, across 2 
groups: patients with good PS and patients with poor PS. Among patients with 
good PS, there were significant differences between those receiving 
chemotherapy and those not receiving it by age at diagnosis, and the patient’s 
Charlson comorbidity index. Among patients with poor PS, there were significant 
differences between those receiving chemotherapy and those not receiving it by 
age and median household income in the patient’s neighborhood. Among the 
good PS group, patients who received chemotherapy had significantly greater 
survival; the mean survival time was 21.7 months (SD, 20.6) for patients who 
received chemotherapy versus 15.6 months (SD, 23.0) for those who did not, 
while 61.7% of patients in this group who received chemotherapy died by the end 
of the study period compared with 68.8% of those without chemotherapy. 
Similarly, significant survival differences were recorded among the poor PS 
group; patients with chemotherapy had a mean survival time of 13.6 months (SD, 
19.1) compared with 7.9 months (SD, 12.8) for those without chemotherapy, and 
84.6% of those receiving chemotherapy in this group died by the end of the study 
period compared with 85.1% of those not receiving chemotherapy. 
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Table 12. Sample Characteristics and Survival, by Performance Status (PS) and 
Choice of Chemotherapy Receipt or Non-Receipt, for Lung Cancer Stages II-IV 
(n = 406) 
 
 Good PS1 (n = 320) Poor PS2 (n = 86) 
Chemo 
(n = 243) 
No Chemo 
(n = 77) 
Chemo 
(n = 39) 
No Chemo 
(n = 47) 
Demographic Characteristics     
  Average age at diagnosis (SD) 65.5 (8.5)3 71.4 (8.9)3 66.9 (9.0)4 71.1 (7.5)4 
  Gender (%)     
          Female  41 47 36 36 
          Male  59 53 64 64 
  Race (%)     
          Black 26 30 31 36 
          White 72 66 69 58 
          Other   2   4   0   6 
Clinical Characteristics     
  AJCC stage (%)     
          II 11 12 15   6 
          III 44 42 23 39 
          IV 45 48 62 55 
  Average Charlson comorbidity index (SD)   1.0 (1.4)3   1.4 (1.5)3   1.9 (2.0)   2.3 (2.3) 
Socioeconomic Characteristics     
  Pct with college degree (SD)   7.1 (6.0)   6.1 (4.9)   6.7 (5.9)   6.9 (4.4) 
  Median household income in $1000s (SD) 50.4(22.2)  47.6(19.8) 52.4(27.8)4 42.7(16.6)4 
Treatment(s) Received     
  No treatment (%)    - 42    - 45 
  Surgery only (%)    -   5    -   2 
  Radiation therapy only (%)    - 52      - 53 
  Chemotherapy only (%) 17    - 31    - 
  Surgery + radiation therapy (%)    -   1    -    - 
  Surgery + chemotherapy (%)   8    -    -    - 
  Radiation + chemotherapy (%) 62    - 64    - 
  Surgery + radiation + chemotherapy (%) 13    -   5    - 
Survival     
   Mean survival time in months (SD) 21.7(20.6) 15.6(23.0) 13.6(19.1)  7.9(12.8) 
   Died by end of study period (%) 61.7 68.8 84.6 85.1 
 
                                                 
1
 Good PS: ECOG 0-2 
2
 Poor PS: ECOG >2 
3
 Among patients with good PS, significant difference by chemotherapy receipt/non-receipt, at 5% 
level  
4
 Among patients with poor PS, significant difference by chemotherapy receipt/non-receipt, at 5% 
level 
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Survival 
 To better understand the factors associated with improved survival, 
univariate and multivariate analyses were performed using patient 
characteristics. The 2SRI analysis found that the residual from the first equation, 
explaining factors associated with chemotherapy receipt, was not a significant 
regressor in the second equation (survival model). Since the receipt of 
chemotherapy was not found to be endogenous in the good PS two-stage model, 
these preliminary findings are shown in the appendix, but excluded from final 
results. 
Overall median survival was longer for patients who received 
chemotherapy in both the good and poor PS groups. Survival for patients who 
received chemotherapy, regardless of PS, was superior to that of patients who 
did not receive chemotherapy (Figure 1). 
 Table 13 lists the adjusted hazard ratios for the good PS group. The 
sample is stratified by receipt of chemotherapy. Among patients with good PS, 
the multivariate Cox regression analysis found that stage IV diagnosis (hazard 
ratio [HR], 2.19) was significantly associated with a higher risk of dying, whereas 
the receipt of chemotherapy (HR, 0.64), surgery (HR, 0.33), and female gender 
(HR, 0.66) were all significantly associated with a lower risk of dying. The 
residual from the first-stage equation was not significantly associated with the 
dependent variable and was dropped from this table, but included in the 
appendix. This suggested that there was no evidence of endogeneity for 
chemotherapy in the good PS model. 
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 Alternative models that considered patients with PS=2 under the poor PS 
group are presented in Appendix B. The major difference compared with the 
baseline models is that chemotherapy was not significantly associated with a 
lower risk of death for patients with good PS, when PS 2 patients are excluded 
from this group.  
Among patients with poor PS (table 14), the multivariate Cox regression 
found that stage IV diagnosis (HR, 1.90) was associated with a higher risk of 
dying, whereas the receipt of chemotherapy (HR, 0.04) was associated with a 
lower risk of dying. Female gender (HR, 0.61) and living in a neighborhood with a 
higher rate of college graduates (HR, 0.93) were associated with a lower risk of 
dying. However, these associations were not significant at P < 0.05. There is also 
evidence of an association between the residual from the first-stage equation and 
the risk of dying (P = 0.06), suggesting that unobservable disturbances from the 
first stage equation are associated with the dependent variable in the poor PS 
Cox model. 
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Figure 1. Kaplan-Meier Curves by Chemotherapy Receipt for Patients with Good 
Performance Status (PS)1 (A; N = 320) and Poor PS2 (B; N = 86) 
 
A 
 
 
B 
 
 
                                                 
1
 Good PS: ECOG 0-2 
2
 Poor PS: ECOG >2 
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Table 13. Multivariate Cox Proportional Hazards Model of Survival for Good 
Performance Status (PS) Patients Diagnosed With Stage II-IV Lung Cancer 
between 2000 and 2007 (N = 320) 
 
Performance Status = Good1 Parameter Hazard Ratio P Value 
Treatment Received    
  Chemotherapy -0.45 0.64 0.01 
  Surgery -1.12 0.33 <.01 
  Radiation  0.18 1.20 0.30 
Patient Demographics    
  Age at diagnosis (years) 0.01 1.01 0.20 
  Gender = female -0.41 0.66 <.01 
  Race = white 0.29 1.34 0.12 
Clinical Characteristics    
  Stage IV at diagnosis 0.78 2.19 <.01 
  Charlson comorbidity index 0.02 1.02 0.75 
Socioeconomic Characteristics    
  College degree 0.01 1.01 0.56 
  Median income ($1000s) -0.01 0.99 0.07 
Model Characteristics    
   Likelihood ratio, χ2(10)       94.0   
   Probability > χ2 0.00   
                                                 
1
 Good PS: ECOG 0-2 
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Table 14. Multivariate Cox Proportional Hazards Model of Survival for Poor 
Performance Status (PS) Patients Diagnosed With Stage II-IV Lung Cancer 
between 2000 and 2007 (N = 86)  
 
Performance Status = Poor1 Parameter Hazard Ratio P Value 
Treatment Received    
  Chemotherapy -3.20 0.04 0.03 
   Surgery     -15.33 0.00 0.98 
  Radiation  0.29 1.34 0.30 
Patient Demographics    
  Age at diagnosis (years) -0.04 0.96 0.09 
  Gender = female -0.50 0.61 0.06 
  Race = white -0.32 0.73 0.33 
Clinical Characteristics    
  Stage IV at diagnosis 0.64 1.90 0.02 
  Charlson comorbidity index 0.08 1.08 0.14 
Socioeconomic Characteristics    
  College degree -0.08 0.93 0.07 
  Median income ($1000s) 0.02 1.02 0.16 
First Stage Residual 1.20 3.31 0.06 
Model Characteristics    
   Likelihood ratio, χ2(10) 37.4   
   Probability > χ2 0.00   
                                                 
1
 Poor PS: ECOG >2 
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4.4 Discussion 
 To my knowledge, this is the first study that examines the impact of 
guideline recommended (and non-recommended) chemotherapy on survival of 
lung cancer patients in a large cohort of managed care enrollees. There are 
several findings to note from this study. First, all else equal, insured patients with 
good PS who receive chemotherapy have significantly higher survival compared 
with those with no chemotherapy. Second, similar patients with poor PS who 
receive chemotherapy also have significantly higher survival compared with 
those who do not receive chemotherapy. The two-stage model used to explain 
this relationship suggests that other unobservable factors associated with the 
receipt of chemotherapy in poor PS patients may have a positive impact on 
survival. Further, by considering the alternative models that used the pre-2009 
guidelines in defining chemotherapy appropriateness, it seems that 
chemotherapy may be especially beneficial for PS 2 patients. This finding 
explains why the guidelines were revised to recommend chemotherapy for this 
group of patients. 
 These conclusions should be interpreted in the light of several important 
limitations. First, these findings are based on a cohort of insured cancer patients, 
and survival rates as well as adherence rates may differ among an uninsured 
population. Similarly, models were developed on a sample of patients receiving 
their care from one delivery system located in a large urban area. Therefore, care 
should be taken when generalizing findings to other delivery settings and locales. 
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Furthermore, models may exclude important factors associated with survival 
including variations across health systems and geographical regions. 
 Second, some patients who were prescribed chemotherapy but did not 
live long enough to receive treatment would be counted as having not received 
chemotherapy. If survival after diagnosis predicts chemotherapy use, this could 
bias survival in favor of those who received chemotherapy. 
 Finally, it is not known whether chemotherapy was given with good intent 
in lieu of hospice for palliative reasons to those with poor PS, and if there was 
any subsequent impact on symptom burden or hospitalizations for side effects. 
 
74 
 
 
CHAPTER 5. CONCLUSION 
Performance status is widely recognized as a predictor for treatment 
appropriateness and reducing chemotherapy to patients with poor PS has been 
recommended as one way to increase health care quality and reduce costs (T. J. 
Smith, B. E. Hillner 2011). This is the first study to use observational data to 
estimate PS for lung, or any other, cancer patients. Despite good predictability of 
PS using this model, a predicted version will always be second-best to having the 
actual PS data. Tumor registries should include PS as a required field in order to 
assess quality of care. 
Using the first large cohort of patients with lung cancer for whom PS is 
known, this study found the overall adherence to evidence-based guidelines for 
chemotherapy treatment to be 71%.  Among those whose care was non-
concordant with guideline recommendations, 19% did not receive chemotherapy 
when it was indicated and 10% received chemotherapy when it was not 
recommended. This study recorded a higher adherence rate than  previous lung 
cancer studies that used population-based Medicare data and did not control for 
PS (P. B. Bach et al. 1999;C. C. Earle et al. 2000;T. J. Smith et al. 1995;A. L. 
Potosky et al. 2004) and found that older patients are less likely to use 
chemotherapy, regardless of their PS.  
The higher the median household income in the patient’s neighborhood of 
residence the more likely they are to be out of compliance in both directions, both 
“overusing” and “underusing” chemotherapy. Unlike other studies that analyzed 
Medicare claims data, this study considered a rarely studied managed care 
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cohort that included younger patients as well as older ones, although the median 
age of 67 was close to the US median age at diagnosis of 71 (National Cancer 
Institute 2010). Another notable difference of this study is that it found no racial 
differences in the receipt of chemotherapy (either underuse or overuse), which 
suggests that disparities may be attributable to other factors.  Among the 
urban/suburban population studied here, this study did not find travel distance to 
be associated with recommended chemotherapy treatment. Instead, it was found 
that if fewer households in a patient’s neighborhood had access to a car, this 
travel barrier was associated with underuse of chemotherapy relative to guideline 
recommendations. This finding suggests that patients without access to a car 
may have difficulty reaching a clinic, even when there is a clinic a relatively short 
distance from their home. This suggests a helpful question to ask on intake 
screening: “Will you have difficulty getting to your next appointment?” 
Finally, this is the first study that examines the impact of guideline 
recommended chemotherapy on survival of lung cancer patients in a large cohort 
of managed care enrollees. The study found that regardless of PS, patients who 
received chemotherapy had significantly higher survival compared with those 
who did not receive chemotherapy, although the model suggests that other 
unobservable factors associated with the receipt of chemotherapy in poor PS 
patients may have a positive impact on survival. 
This study is not without its limitations. First, subjectivity is present in the 
assignment of PS. It is documented that PS scales are subjective in nature, and 
when estimated by physicians they are known to be prone to error, usually being 
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overestimated. Second, the study relies on a relatively small sample that is 
specific to one health care delivery system, located in a large urban area. The 
findings of this study may not be generalized, especially to non-urban 
populations. Third, the models in this study may exclude relevant measures, 
including provider characteristics and variations across health systems and 
geographic areas. Also, these findings are based on an insured cohort of lung 
cancer patients, and may be different among the uninsured. Finally, this study 
was not intended to assess specific chemotherapy regimens. Therefore it is not 
known whether chemotherapy was given with good intent in lieu of hospice for 
palliative reasons to those with poor PS.  
Given the limitations of the current study, several ideas for future research 
emerge. First, the analysis could be expanded to include multiple health systems, 
with a larger cohort of patients and geographic variations. The advantage of 
having a larger, more diverse cohort to study will allow for the examination of 
more factors, including provider characteristics and health system variations, and 
allow for the study of treatment costs. A priority in the study of costs would be to 
define a treatment episode for lung cancer patients and measure per episode 
costs. Once the treatment episode is defined, cost effectiveness analysis could 
be performed using survival and cost resulting from lung cancer treatment.  
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APPENDIX 
Appendix A. Factors Associated with Non-Receipt of Chemotherapy among 
Patients with Good Performance Status (PS) (N = 276) and Receipt of 
Chemotherapy among Patients with Poor PS (N = 130) 
 
Performance Status = Good1 Odds of Under Use (95% CI) P Value 
Patient Demographics   
  Age at diagnosis (years) 1.10 (1.06-1.14)    <0.01 
  Gender = female 1.37 (0.74-2.54)      0.31 
  Race = white 0.71 (0.31-1.64)      0.43 
Clinical Characteristics   
  Charlson comorbidity index 1.20 (0.97-1.49)      0.10 
Socioeconomic Characteristics   
  College degree 0.96 (0.88-1.04)      0.35 
  Median income ($1000s) 1.02 (1.00-1.05)      0.09 
Access to Treatment   
  Pct without vehicle   5.12(0.55-47.79) 0.15 
  Distance to chemo facility              1.00 (0.98-1.03) 0.56 
Guidelines   
  Year of diagnosis < 2003   2.29 (1.22-4.32) 0.01 
Model Performance   
Pseudo-R2   0.14                             
C-statistic  0.75 
Performance Status = Poor2 Odds of Over Use (95% CI) P Value 
Patient Demographics  
  Age at diagnosis (years) 0.93 (0.89-0.98)       0.01 
  Gender = female 0.78 (0.35-1.74) 0.54 
  Race = white 0.94 (0.38-2.35) 0.90 
Clinical Characteristics   
  Charlson comorbidity index 0.99 (0.81-1.20) 0.91 
Socioeconomic Characteristics   
  College degree 1.00 (0.90-1.10) 0.91 
  Median income ($1000s) 1.03 (1.00-1.06) 0.09 
Access to Treatment    
  Pct without vehicle 0.91(0.11-7.56) 0.93 
  Distance to chemo facility 0.98(0.93-1.03) 0.40 
Guidelines   
  Year of diagnosis ≥ 2003 2.59(1.12-6.00) 0.03 
Model Performance   
  Pseudo-R2   0.13 
  C-statistic  0.71 
 
                                                 
1
 Good PS: ECOG 0-2 
2
 Poor PS: ECOG>2 
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Appendix B. Two-Stage Residual Inclusion Method: Multivariate Cox Proportional 
Hazards Models with Residuals from Chemotherapy Receipt Logit Regression, 
(N = 320) 
 
Performance Status = Good1 Parameter Hazard Ratio P Value 
Treatment Received    
  Chemotherapy -1.54 0.21 0.15 
  Surgery -1.12 0.33 <.01 
  Radiation  0.19 1.21 0.29 
Patient Demographics    
  Age at diagnosis (years) -0.00 1.00 0.91 
  Gender = female -0.48 0.62 <.01 
  Race = white 0.38 1.46 0.06 
Clinical Characteristics    
  Stage IV at diagnosis 0.79 2.20 <.01 
  Charlson comorbidity index 0.02 1.00 0.97 
Socioeconomic Characteristics    
  College degree -0.00 1.02 0.38 
  Median income ($1000s) -0.02 0.99 0.04 
Residual 0.47 1.60 0.30 
Model Characteristics    
   Likelihood ratio, χ2(10)       95.0   
   Probability > χ2 0.00   
 
 
                                                 
1
 Good PS: ECOG 0-2 
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Appendix C. Alternative Models with Pre-2009 Definition of Performance Status 
(PS): Multivariate Cox Proportional Hazards Model of Survival for Patients 
Diagnosed With Stage II-IV Lung Cancer between 2000 and 2007  
 
Performance Status = Good1 Parameter Hazard Ratio P Value 
Treatment Received    
  Chemotherapy -0.34 0.71 0.09 
  Surgery -1.15 0.32 <.01 
  Radiation  0.21 1.24 0.28 
Patient Demographics    
  Age at diagnosis (years) 0.01 1.01 0.34 
  Gender = female -0.39 0.67 0.02 
  Race = white 0.49 1.63 0.02 
Clinical Characteristics    
  Stage IV at diagnosis 0.74 2.09 <.01 
  Charlson comorbidity index 0.09 1.09 0.18 
Socioeconomic Characteristics    
  College degree 0.02 1.02 0.40 
  Median income ($1000s) -0.01 0.99 0.03 
Model Characteristics    
   Likelihood ratio, χ2(10)       78.0 N=276  
   Probability > χ2 0.00   
 
Performance Status = Poor2 Parameter Hazard Ratio P Value 
Treatment Received    
  Chemotherapy -2.84 0.06 0.04 
   Surgery -2.48 0.08 0.02 
  Radiation  0.18 1.20 0.40 
Patient Demographics    
  Age at diagnosis (years) -0.01 0.98 0.38 
  Gender = female -0.55 0.58 0.01 
  Race = white -0.27 0.76 0.29 
Clinical Characteristics    
  Stage IV at diagnosis 0.60 1.83 0.01 
  Charlson comorbidity index 0.01 1.01 0.83 
Socioeconomic Characteristics    
  College degree -0.02 0.98 0.50 
  Median income ($1000s) 0.01 1.01 0.22 
Residual 0.96 2.62 0.10 
Model Characteristics    
   Likelihood ratio, χ2(10) 41.3 N=130  
   Probability > χ2 0.00   
                                                 
1
 Good PS: ECOG 0-1 
2
  Poor PS: ECOG >1 
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Evidence-based guidelines recommend chemotherapy for medically fit 
patients with stage II-IV non-small cell lung cancer (NSCLC). Adherence to 
chemotherapy guidelines has rarely been studied among large populations, 
mainly because performance status (PS), a key component in assessing 
chemotherapy appropriateness, is missing from claims-based datasets. Among a 
large cohort of patients with known PS, this dissertation describes chemotherapy 
use relative to guideline recommendations and identifies patient factors and 
outcomes associated with guideline concordant use. Among these patients 29% 
do not receive guideline recommended chemotherapy treatment, missing 
opportunities for cure or receiving chemotherapy with more risk of harm than 
benefit, thereby likely foregoing beneficial palliation. Care concordant with 
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guidelines is influenced by age, and economic considerations, such as income, 
and transportation barriers. Guideline adherent use of chemotherapy reduced 
risk of dying. Overuse of chemotherapy also reduced risk of dying. Among poor 
PS patients, stage IV diagnosis was also associated with survival. Chemotherapy 
has positive effects on survival for both good and poor PS patients. In the poor 
PS group, the relationship between chemotherapy and survival is affected by 
other unobservable factors. 
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